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In the twenty-first century, heart failure (HF) represents the most rapidly growing 
cardiovascular condition worldwide (1). Per definitionem, the term of HF defines a 
clinical syndrome when characteristic symptoms (e.g. breathlessness, ankle swelling and 
fatigue) are present, and the development of these typical symptoms are related to the 
structural and/or functional abnormalities of the heart (2). According to the current 
reports, the estimated prevalence of HF reaches 26 million (3). The projections for 2030 
are even more alarming due to the aging trend of the human population (4). Besides the 
high patient prevalence, chronic HF (CHF) is associated with significant patient 
morbidity and mortality, with the 5-year mortality rate approaching 50% (5). Patients 
with CHF have a substantially worse quality of life when compared to both healthy 
individuals and patients suffering from other chronic health conditions (4). Finally, the 
financial cost of HF-associated medical treatment is substantial. In 2010, the estimated 
cumulative cost of HF was 39.2 billion American dollars in the United States (5). 
Therefore, despite the advances in CHF management, the continuing high prevalence of 
this condition coupled with high mortality rate, poor quality of life and severe financial 
burden for the health care system warrants further therapeutical improvements.  
A wide range of pathological conditions can lead to the development of CHF. Among 
them, myocardial ischemia, primary cardiomyopathies (due to genetic background) and 
secondary cardiomyopathies (due to toxic, infectious or immunological reasons) are 
responsible for the majority of HF cases (1). It is noteworthy that most forms of ischemic 
heart disease ([IHD] e.g. following an extensive myocardial infarction) and 
primary/secondary cardiomyopathies are associated with irreversible myocardial insult. 
Therefore, in this patient population heart transplantation often remains the only curative 
medical therapy. 
Besides the above-mentioned etiologies, chronic hemodynamic overload (pressure 
overload [PO] in case of arterial hypertension [AH], aortic stenosis [AS] and volume 
overload [VO] in case of aortic/mitral regurgitation) remains one of the main contributors 
to HF development (1). Of particular interest, a great body of scientific evidence supports 
the notion that termination of hemodynamic overload could result in a state of reverse 
remodeling with substantial improvement in cardiac structure and function (6). 




patients with AS (via transcatheter aortic valve implantation [TAVI]) can receive 
definitive medical therapy without undergoing open heart surgery (7). Thus, the unique 
opportunity for successful medical interventions has brought hemodynamic overload-
induced HF into the focus of interest.  
Parallel to the clinical investigations, substantial efforts have been made in the field of 
experimental research to better understand the (patho)physiology of hemodynamic 
overload-induced remodeling and unloading-evoked reverse remodeling. Due to the 
extremely high prevalence of AH and AS in Western societies, the majority of preclinical 
studies has focused on PO-induced HF and pressure unloading-evoked myocardial 
reverse remodeling. These investigations have revealed important findings which might 
serve as a basis for the optimization of current medical therapies. However, there is still 
a considerable number of unsolved questions, which warrants further preclinical 
experimentations.  
 
2.1. Clinical conditions associated with pressure overload of the left ventricle 
In case of PO, the afterload (load that the heart has to pump against during systole) of 
the left ventricle (LV) is increased. The two most common clinical conditions, which are 
associated with increased afterload of the LV are AH and AS.  
Arterial hypertension. AH is generally defined as a sustained systolic blood pressure 
(SBP) at least 140 mmHg and/or diastolic blood pressure (DBP) at least 90 mmHg (8). 
Based on the latest surveys, the estimated global prevalence of AH was 1.13 billion in 
2015 (9). Another terrifying fact that the prevalence of AH is exponentially increasing by 
age (10). Therefore, due to the aging trend of the Western population, the epidemiological 
burden of AH is expected to progress in the following years.  
Aortic stenosis. AS refers to the pathophysiological state when the outflow tract of the 
LV is narrowed. AS can be divided into the following subcategorizes: supravalvular, 
valvular and subvalvular. In the present thesis, AS will refer to valvular AS. Data from 
the Euro Heart Survey has revealed that AS is the most common single native valvular 
left-sided heart disease in Europe (11, 12). Besides its high prevalence, the significance 
of AS is given by the fact that approximately 67,500 aortic valve replacement (AVR) 




AS also typically affects the elderly. Correspondingly, the prevalence of AS increases by 
age, reaching almost 10% in people over 80 years (14).  
 
2.2. Pressure overload-induced pathological myocardial remodeling 
Under sustained PO the heart undergoes extensive remodeling, which affects both the 
myocardium, the extracellular matrix (ECM), and the intramyocardial coronary arteries 
(15, 16). The remodeling process has some initial advantageous components that 
promotes the early adaptation of the ventricles to the increased hemodynamic loading 
conditions. However, in the long term the PO-associated molecular, cellular and 
histological alterations become maladaptive and contribute to the progression of HF. It is 
also important to point out that the remodeling process which can be observed in 
physiological states (e.g. regular exercise-induced or pregnancy-evoked myocardial 
remodeling) is characteristically different from chronic PO-induced remodeling (17). 
Therefore, the terminology of pathological remodeling is used to distinguish 
hemodynamic overload-induced maladaptive alterations from other physiological 
processes.  
 
2.2.1. Increased systolic wall stress: the main driving force of pressure overload-
induced pathological remodeling 
In case of PO, the primary stimulus of pathological remodeling is increased wall 
tension (mechanical load) on the level of the individual cardiac cells (18). Traditionally, 
Laplace’s law has been used to describe wall tension. According to Laplace’s equation 
(T=P*r/2h), wall tension (T) is directly related to ventricular pressure (P) and ventricular 
radius (r) and inversely related to ventricular wall thickness (h) (19). In case of PO (AS, 
AH), systolic ventricular pressure is elevated leading to increased wall stress. Of 
particular interest, cardiac cells possess specific sensors (the so called mechano-sensors), 
which make them able to convert the mechanical stimulus (increased systolic wall 
tension) into specific biochemical signals (20). These initial biochemical signals further 
activate distinct intracellular signal transduction pathways that eventually lead to 
pathological remodeling. The main characteristics of PO-induced pathological 
remodeling on the structural, molecular and functional level is summarized in the 





2.2.2. Pressure overload-induced structural alterations 
2.2.2.1. Myocardial hypertrophy 
The most fundamental structural finding in case of chronic LV PO is myocardial 
hypertrophy. Cardiac hypertrophy is broadly defined as an increase in heart mass (21). 
Since cardiomyocytes are terminally differentiated cells with very low ability for 
proliferation, cardiomyocyte hypertrophy rather than cardiomyocyte hyperplasia 
underpins the increase in heart mass (22).  
It is noteworthy to mention that cardiomyocyte hypertrophy manifests promptly after 
induction of PO. Accordingly, the development of myocardial hypertrophy can be already 
detected 2 days after PO induction under standard laboratory conditions (23). These 
findings call attention to the fact that cardiomyocytes are extremely sensitive to an 
increase in afterload.  
According to the conventional interpretation of Laplace’s law, the increase in 
cardiomyocyte size is a compensatory reaction as it reduces systolic wall tension through 
the thickening of the LV wall. However, this long-standing hypothesis has been 
reconsidered, as it was demonstrated that normalization of wall stress may not be 
necessary for the adaptation to sustained hemodynamic overload (24). On the contrary, 
the Framingham Heart study has yielded unequivocal evidence that LV myocardial 
hypertrophy (LVH) increases the risk for cardiovascular morbidity and mortality (25). 
Hence, to date, PO-induced LVH is generally considered to be deleterious.  
On the subcellular level, the hypertrophic response of the cardiomyocytes consist of 
altered gene expression, intensified rate of protein synthesis and organization of the 
synthesized contractile proteins into sarcomeres (21). In case of PO-evoked remodeling, 
the freshly created sarcomeric units are placed parallel within the cells, which subcellular 
localization mostly increases the width of the cardiomyocytes (21). Consistent with this 
ultrastructural pattern, clinical and experimental investigations have reported that PO-
induced remodeling is predominantly associated with thickening of the ventricular walls 
with no or only moderate chamber dilatation (26, 27). Consequently, concentric LVH is 





2.2.2.2. Myocardial fibrosis 
Another hallmark of PO-induced structural remodeling is myocardial fibrosis (28). 
Myocardial fibrosis generally manifests later than cardiomyocyte hypertrophy, 
representing a maladaptive structural milestone in the progression of PO-induced LVH to 
decompensated HF. Importantly, myocardial fibrosis can be subcategorized into 
replacement and reactive fibrosis (including interstitial and perivascular fibrosis) (29). 
Chronic PO-induced remodeling is predominantly associated with reactive fibrosis. 
Nevertheless, at advanced stages of PO-induced LVH, replacement fibrosis also 
manifests (30).  
Replacement fibrosis. Replacement (or reparative) fibrosis occurs following 
macroscopic (the most typical pathophysiological situation is that takes place after 
myocardial infarction) or microscopic myocardial injury and aims to replace the 
irreversibly damaged cardiac tissue (31). At severe stages of PO-induced HF, different 
forms of cell death become activated (e.g. apoptosis (32)), which collectively result in 
substantial loss of myocardial tissue. Hence, at advanced stages of PO-induced HF, 
replacement fibrosis is often observed (33). 
Reactive interstitial fibrosis. In contrast to replacement fibrosis, reactive fibrosis is the 
consequence of direct stimulation of fibroblasts without cellular injury (31). Fibroblast 
stimulation in PO involves complex pathomechanisms. Increased mechanical stress 
(enhanced systolic wall stress) has been implicated as one of the main pathological stimuli 
(34). Importantly, fibroblasts have mechano-sensors embedded in their extracellular 
membrane similar to cardiomyocytes (35). Therefore, fibroblasts are also capable to 
directly sense the physical stimuli of increased wall stress, converting it to pro-fibrotic 
biochemical signals. Furthermore, increased wall stress also determines fibroblast 
function indirectly via cardiomyocyte-fibroblast cross-talk. In addition inflammation, 
oxidative stress and mast cell infiltration/degranulation have been also suggested to 
contribute to the development of interstitial fibrosis in PO-induced HF (29). All of these 
mechanisms eventually promote the transformation of fibroblasts into myofibroblasts 
(36). These transformed cells are mainly responsible for the excessive synthesis of 
different ECM components (e.g. distinct types of collagens, fibronectin) (29). However, 
it must be noted that PO-induced ECM remodeling does not simply implicate the 




simultaneous degradation of important scaffold proteins. Of particular interest, these 
pathological degrading processes disrupt the integrity of the cellular-ECM network, 
leading to substantial alterations in LV geometry. The molecular background for the 
degradation process is supported by a group of distinct enzymes, the so-called matrix 
metalloproteinases (MMP). Under physiological conditions, the biological action of 
MMPs is tightly regulated on the transcriptional, translational and posttranslational levels 
(37). In contrast, in advanced stages of PO-induced HF, both the expression, the activation 
and the inhibition of MMPs become disturbed, leading to an uncontrolled breakdown of 
important ECM components and consequently LV dilatation (38).  
Reactive perivascular fibrosis. Perivascular fibrosis is also an important pathogenic 
feature of PO-induced LVH and HF (39). This is underpinned by the fact that in certain 
clinical (e.g. in AH) and experimental (e.g. abdominal aortic banding [AB]) forms of PO, 
hypertension is also present in the coronary artery system. In these cases, the elevated 
blood pressure in the small intramyocardial arteries induces inflammation in the arterial 
walls (40). This inflammatory reaction evokes the transmigration of macrophages into the 
perivascular space. The accumulated macrophages subsequently activate fibroblasts 
located around the arteries, eventually inducing reactive perivascular fibrosis.  
 
2.2.3. Molecular markers of pressure overload-induced pathological remodeling: 
reactivation of the fetal gene program 
During fetal development the LV is associated with a specific gene expression profile 
termed as the “fetal gene program” (41). Importantly, under physiological conditions, this 
characteristic gene expression pattern cannot be observed after birth. However, in case of 
PO-induced pathological LVH the gene expression profile of the postnatal heart 
resembles that of the fetal gene program (42, 43). The most widely known features of the 
fetal gene program are the switch of the myosin heavy chain (MHC) isoforms and the 
increased ventricular expression of the atrial natriuretic peptide (ANP).  
MHC isoform switch. Myosin II is a motor protein that is required for muscle 
contraction in myocytes. Myosin II is a hexameric enzyme, consisting of two MHCs and 
four myosin light chains (44). The MHC has an actin-binding site and an ATP hydrolysis 
site. Based on the enzymatic activity of the ATP hydrolysis site, two isoforms of MHC 




the lower actomyosin ATPase activity (44). During fetal development the ratio of β/α-
MHC expression is relatively high in the ventricles. However, this ratio substantially 
decreases after birth. It is noteworthy that the isoform switch occurs to a different extent 
in rodents and humans. Accordingly, α-MHC makes up 90% of the total MHC in the 
postnatal rodent ventricles (45). On the contrary, β-MHC remains the dominant isoform 
in “adult” human ventricles. The discrepancy between humans and rodents might be 
explained by the robust differences in heart rate (HR), with rats on average demonstrating 
6-7 times higher HR than humans (46). Despite the inter-species differences, the relative 
ratio of β/α-MHC has been found to increase in both humans and rodents in PO-induced 
pathological LVH and HF. Due to the high baseline expression of β-MHC, the increment 
of β/α-MHC is mainly the consequence of the reduction of α-MHC in humans (44, 45). 
On the contrary, intensified expression of β-MHC and decreased expression of α-MHC 
equally contribute to the altered β/α-MHC ratio among rodents (47).  
Ventricular ANP expression. Natriuretic peptides (NPs) are endocrine factors with 
natriuretic, diuretic and vasorelaxant effects on the cardiovascular system (42, 48). Three 
main types of NPs exist, including ANP, B-type NP (BNP) and C-type NP. ANP gene 
expression is observed in the fetal LV (49). However, the expression of ANP is restricted 
to the atria in the postnatal heart under physiological conditions. In contrast, during the 
development of congestive CHF, robust elevations in mRNA levels of ANP have been 
documented in ventricular samples (49, 50). Of particular interest, recent experimental 
studies have discovered that NPs mediate anti-hypertrophic paracrine/autocrine signaling 
in the myocardium. In more details, cardiomyocytes have NP receptors that are coupled 
with the particulate guanylate cyclase (pGC) enzyme. In case of ANP/BNP binding, the 
pGC enzyme catalyzes the formation of the second messenger cyclic guanosine 
monophosphate (cGMP) (42). The elevated cytoplasmic cGMP content potentiates the 
activity of the enzyme protein kinase G, which subsequently downregulates many pro-
hypertrophic signaling pathways. Thus, although ANP is a member of the fetal gene 
program, its increased expression during chronic LV PO also represents an inbuilt break 





2.2.4. Pressure overload-induced functional alterations 
The in vivo assessment of LV function under sustained PO is technically challenging. 
The difficulty arises due to the fact that the robust increment in afterload makes the 
conventional load-dependent parameters inappropriate to characterize in vivo LV 
function in pathological conditions associated with sustained PO. Hence, to adequately 
investigate alterations of LV function in PO-induced LVH and HF, the confounding effect 
of different loading conditions has to be eliminated. To date, invasive pressure-volume 
(P-V) analysis represents the “gold standard” technique to assess distinct aspects of in 
vivo LV function independently from loading conditions (52, 53). Therefore, our 
knowledge concerning the alterations in systolic and diastolic LV function during the 
development of PO-induced LVH and HF are mainly derived from P-V analysis data.  
 
2.2.4.1. Left ventricular systolic function in chronic pressure overload 
Numerous research groups have aimed at measuring systolic function in PO-induced 
LVH. These investigations have consistently reported that LV systolic function is 
maintained (ejection fraction [EF] is preserved) at a relatively early stage of PO-induced 
pathological remodeling but deteriorates at advanced stages (EF is reduced). Of particular 
interest, it has been demonstrated that the time point at which decompensation of systolic 
function takes place is dependent on the severity of the PO. Accordingly, in rodent models 
with extremely elevated LV PO (e.g. severe aortic banding [AB]), rapid deterioration of 
LV systolic function is frequently observed (54). In contrast, in animal models with 
relatively moderate LV PO (e.g. spontaneous hypertensive rat [SHR] strain), a 
substantially longer “compensated” phase precedes the development of systolic HF (55). 
In clinical practice, the majority of patients with AH and AS demonstrate preservation of 
LV global systolic function for a relatively long period of time.  
Previous clinical and experimental studies using P-V analysis have noted that the load-
independent indices of LV contractility are markedly increased at the early stage of PO-
induced LVH (47, 56, 57). Based on these findings, it has been postulated that 
augmentation of LV contractility represents an early compensatory reaction that enables 
the LV to counterbalance the increased arterial afterload. To describe the interaction 
between the contractile state of the LV and the afterload of the connecting arterial system, 




defined as the ratio of arterial elastance ([Ea], an integrative parameter of arterial 
afterload) and LV contractility (measured by the slope [Ees] of the end-systolic pressure-
volume relationship [ESPVR]) (58, 59). In case of PO, Ea is increased. However, the 
increment in LV contractility (Ees) is proportional to the elevation of afterload (Ea) during 
the early stage of PO-induced LVH. As a result, VAC is maintained and systolic function 
(EF) is preserved (57).  
In contrast, during the transition of compensated LVH to systolic HF, a mismatch 
develops between LV contractility and the afterload of the connecting arterial system 
(impaired VAC). Previous experiments have yielded controversial findings, whether 
decrement in LV contractility or increment in arterial elastance underlies the contractility-
afterload mismatch during the progression of PO-induced LVH to systolic HF (60-62). 
As such, further studies utilizing P-V analysis are warranted to better understand the 
decompensation of systolic function in PO-induced LVH. 
 
2.2.4.2. Left ventricular diastolic function in chronic pressure overload 
Diastolic dysfunction is a characteristic feature of PO-induced HF. Of particular 
interest is the observation that impairment of diastolic function frequently precedes the 
deterioration of systolic function in case of PO-induced LVH. Hence, many HF patients 
with long-lasting PO exhibits diastolic dysfunction but preserved systolic performance 
(63). Importantly, data from invasive P-V analysis has revealed that both the active and 
the passive components of diastolic function are impaired in PO-induced HF.  
In order to describe ventricular relaxation independently from loading conditions, the 
active relaxation time constant (Tau) is often calculated by the use of P-V analysis data 
(52). In patients with AS, marked prolongation of Tau has been repeatedly observed, 
indicating severely impaired active relaxation (64, 65). These findings have been 
precisely replicated by numerous animal models of PO-induced HF (47, 57, 66, 67).  
Evaluation of the passive diastolic properties of the LV by P-V analysis relies on the 
calculation of LV end-diastolic pressure (LVEDP) and the slope of the end-diastolic P-V 
relationship (EDPVR) (52). Both of these indices have been found to be greatly increased 
in patients with AS as well as in a wide range of different animal models with sustained 





Figure 1. Summary of pressure overload-induced pathological myocardial remodeling. The 
early stage of pressure overload (PO)-induced left ventricular myocardial hypertrophy (LVH) is 
associated with cardiomyocyte hypertrophy and low level of interstitial and perivascular fibrosis 
on the ultrastructural level. At this stage, diastolic dysfunction is often present, however systolic 
function is preserved. At later stages, further accumulation of interstitial and perivascular collagen 
occurs. In addition, systolic function also deteriorates. AH: arterial hypertension, AS: aortic 
stenosis, PO: pressure overload. Cross sectional whole heart pictures are adapted from Ruppert et 





2.3. Pressure unloading-induced myocardial reverse remodeling 
In recent years, a growing body of clinical data has provided evidence that termination 
of the pathological insult of sustained PO (e.g. by AVR/TAVI in case of AS or by 
antihypertensive medications in case of AH) induces the regression of LVH. This process 
is termed myocardial reverse remodeling and involves the restoration of the physiological 
LV phenotype on the molecular, ultrastructural, geometrical as well as functional level 
(69). In the following sections, different aspects of pressure unloading-induced 
myocardial reverse remodeling are summarized.  
 
2.3.1. Pressure unloading-induced structural alterations 
2.3.1.1. Regression of myocardial hypertrophy 
Clinical and experimental studies have shown that myocardial hypertrophy remains 
reversible even after a long period of sustained PO (70, 71). Correspondingly, substantial 
reduction in LV mass has been documented after different types of pressure unloading 
therapies. Furthermore, the regression of myocardial hypertrophy after TAVI/AVR or 
antihypertensive therapy has been found to follow a characteristic time course. Based on 
these reports, termination of the pathological stimulus of sustained PO leads to a rapid 
regression of LVH (6, 72-78). Of particular interest is the observation that the majority 
of LV mass reduction (approximately two-thirds of the total mass regression) occurs 
during this early phase (within the first 18 months). The initial phase is subsequently 
followed by a second more chronic phase, which continues over several years after the 
correction of the primary hemodynamic abnormality (73, 79).  
Beyond the clinical investigations, animal models have been also utilized to investigate 
the temporal regression of LVH under laboratory conditions. These preclinical studies 
have reported that decrement in myocardial hypertrophy takes place already within 3 days 
of PO termination (80, 81). Furthermore, data from animal experiments have confirmed 
that the prompt regression of LVH is followed by an additional chronic phase under 
standard laboratory circumstances as well (70).  
Furthermore, numerous studies have sought to determine the extent to which the 
hypertrophied myocardium may recover after a successful pressure unloading therapy. 




in case of a long follow-up period after AVR (72, 73). Nevertheless, it has to be noted 
that a “restitutio ad integrum” generally does not occur. One possible explanation for the 
incomplete regression of LVH is that pressure unloading therapies often fail to completely 
alleviate the increased PO. For example, in case of AVR, the prosthetic valve itself may 
create a slight stenosis compared to the absolutely healthy aortic valves (73). Therefore, 
a relatively low level of PO may persist even after successful surgical interventions. The 
residual increment in PO might impede the complete normalization of myocardial 
hypertrophy.  
In addition to the macroscopic findings, ample amount of data has provided evidence 
that reduced cardiomyocyte size (assessed by myocardial fiber diameter or cross sectional 
area) is mainly responsible for the decrement of LV mass on the microscopic level. This 
observation is corroborated by the analysis of endomyocardial biopsies obtained from AS 
patients who underwent AVR (72). Moreover, the detailed histopathological analysis of 
the whole LV myocardium in different animal models has come to the same conclusion 
(82, 83).  
 
2.3.1.2. Regression of myocardial fibrosis 
Regression of myocardial fibrosis after pressure unloading is generally considered to 
be a less efficient process compared to the regression of cardiomyocyte hypertrophy. 
Importantly, as previously mentioned, myocardial fibrosis can be subcategorized into 
replacement and reactive (including perivascular and interstitial) fibrosis. Recent 
investigations have come to the conclusion that these two forms of myocardial fibrosis 
differ in their plasticity. 
Replacement fibrosis. In vivo assessment of myocardial replacement fibrosis (also 
known as focal fibrosis) is carried out by late gadolinium enhancement (LGE) 
cardiovascular magnetic resonance imaging (CMR) (84). Thus, majority of the available 
clinical research data concerning the regression of replacement fibrosis after pressure 
unloading therapy is derived from LGE CMR reports. These studies have revealed that 
replacement fibrosis persists after AVR (6, 30, 85). The irreversible nature of replacement 
fibrosis stands in parallel with the current concept of its development. Accordingly, as 




cardiac cells. Considering that cardiomyocytes have very low proliferative ability, the 
permanent nature of replacement fibrosis after pressure unloading is an expected finding.  
Reactive interstitial fibrosis. The non-invasive, in vivo evaluation of interstitial 
fibrosis has not been feasible for a long period of time. Nevertheless, recent advances in 
CMR imaging technology has made the quantification of interstitial fibrosis possible (75, 
86). Data from current CMR studies along with prior endomyocardial biopsies have 
revealed that interstitial fibrosis is plastic and able to regress on the long term (6, 85, 87). 
However, the time course of interstitial fibrosis regression has been reported to be much 
slower than that of cardiomyocyte hypertrophy. As a consequence, at a relatively early 
time point after pressure unloading, when a substantial reduction in cardiomyocyte size 
(diameter/cross sectional area) has already taken place, the amount of interstitial fibrotic 
tissue often remains unchanged (88, 89). Accordingly, the percent of interstitial fibrosis 
has been reported to even increase at an intermediate stage of myocardial reverse 
remodeling (64, 65). In contrast, at later stages (8-10 years after AVR) the amount of 
extracellular collagen decreases, and hence the percentage of interstitial fibrosis reduces 
as well (65). However, the extent to which interstitial fibrosis regresses after pressure 
unloading therapy is still under intense investigation. Results from experimental studies 
indicate that complete regression of pre-established interstitial fibrosis does not occur, 
even in the long term follow-up (90).  
Reactive perivascular fibrosis. Currently, detection of perivascular fibrosis is only 
accomplished by histological analysis. However, the possibility for carrying out 
myocardial biopsies in AS patients after pressure unloading therapy is limited. Hence, our 
knowledge concerning the reversibility of perivascular fibrosis is mainly derived from 
animal studies. These investigations have revealed that perivascular fibrosis displays 
similar regression to interstitial fibrosis after pressure unloading (91).  
 
2.3.2. Pressure unloading-induced molecular alterations 
Due to the fact that LV mRNA/protein expression analysis requires myocardial tissue 
collection, molecular features of myocardial reverse remodeling has been mainly 
investigated in relevant animal models. These preclinical experiments have provided 
compelling evidence that the regression of LVH after pressure unloading therapy is 




research has also indicated that normalization of the fetal gene program might even 
precede the structural and functional recovery of the hypertrophied and failing 
myocardium (92).  
Furthermore, recent findings have called attention to the fact that those molecular 
alterations that occur during myocardial reverse remodeling are not merely the reverse of 
those that cause LVH and HF (92). Correspondingly, characteristically different gene 
expression profiles have been observed during PO-induced remodeling and pressure 
unloading-evoked reverse remodeling (93). Hence, it seems possible that from a 
molecular point of view the reverse-remodeled heart is not simply the halfway mark 
between PO-induced LVH and the healthy state, but it rather represents a distinct third 
category.  
 
2.3.3. Pressure unloading-induced functional alterations 
2.3.3.1. Recovery of left ventricular systolic function after pressure unloading 
Most of the clinical studies have found that removal of the chronic PO induces a rapid 
improvement in systolic function (94-96). Correspondingly, it has been suggested that 
enhancement of LV systolic performance after pressure unloading therapy does not 
necessarily require a complete normalization of LV structural abnormalities (especially 
fibrosis) (70). These observations raise the possibility that the termination of the increased 
afterload might be sufficient to achieve a prompt improvement in LV systolic function 
without substantial changes in LV contractility. However, a common limiting factor for 
the above mentioned investigations is that LV systolic function has been assessed only 
by load-dependent methods. Hence, more sophisticated hemodynamic characterization 
by P-V analysis is warranted to gain a deeper insight into the rapid recovery of LV systolic 
function after pressure unloading. 
 
2.3.3.2. Recovery of left ventricular diastolic function after pressure unloading 
Contrary to systolic dysfunction, amelioration of PO-induced diastolic dysfunction 
occurs in a slow fashion and usually continues over several years following pressure 
unloading. Interestingly, clinical experience suggests that the two aspects of diastolic 
function, namely passive filling and active relaxation, differ in their reversibility after 




Passive filling. Villari et al. have found that myocardial stiffness follows very 
precisely the changes of interstitial fibrosis in patients with AS undergoing pressure 
unloading therapy (64). As previously mentioned, the percent of interstitial fibrosis may 
even be increased at a relatively early time point after AVR. At this particular stage, 
Villari et al. have observed that myocardial stiffness was also further impaired. In 
contrast, at later stages (8-10 years after AVR) the resorption of interstitial fibrosis 
implied the normalization of myocardial stiffness (64, 65).   
Active relaxation. On the contrary, in the same investigations a significant 
improvement in the active relaxation time constant (Tau) was documented already at an 
intermediate time point after pressure unloading therapy (64). Furthermore, a rapid (2 
weeks after surgery) recovery in active relaxation was also demonstrated by Ikonodimis 
et al. Of particular interest, in the later echocardiographic follow-up study, patients 
undergoing AVR had experienced a significant improvement in myocardial relaxation 
early after surgery, at a time point when regression of LV wall thicknesses has not yet 
occurred (79).  
These clinical findings suggest that improvement of passive filling is immensely 
dependent on the regression of structural abnormalities (mainly fibrosis). On the other 
hand, clinical data indicate that normalization of active relaxation might require less 
structural reverse remodeling. However, experimental results are not available to support 
these phenomena since the effect of complete versus incomplete structural reverse 






Figure 2. Summary of pressure unloading-induced myocardial reverse remodeling. Pressure 
unloading induces a rapid regression of cardiomyocyte hypertrophy leading to substantial 
reduction in left ventricular mass. However, reactive interstitial and perivascular myocardial 
fibrosis often persists at a relatively early stage after pressure unloading. From a functional point 
of view, the early phase of reverse remodeling is characterized by improved systolic function but 
impaired diastolic function. In contrast, at later stages, reactive myocardial fibrosis also regresses, 
resulting in the amelioration of diastolic function. AVR: aortic valve replacement, TAVI: 
transcatheter aortic valve implantation. Cross sectional whole heart pictures are adapted from 




2.4. Sex differences in pressure overload-induced pathological remodeling and 
pressure unloading-induced reverse remodeling 
Sex differences have been increasingly recognized in various frequent cardiovascular 
disorders, such as in IHD and hemodynamic overload-induced HF. Importantly, sex-
related discrepancies have been found to affect both the pathophysiology, the clinical 
manifestation and the epidemiology of cardiovascular pathologies (97, 98). Recent 
investigations have shed light on the molecular basis, which might be responsible for the 
observed differences between men and women. These subcellular mechanisms involve 
sex chromosomes-derived genetic differences, diversity in epigenetic regulation (due to 
characteristic microRNA expression) and the effects of different sex steroid hormones 
(98). Although, all of the three proposed mechanisms may be involved, the majority of 
previous investigations have focused on the role of sex steroid hormones (mainly 
estrogen). The observation, which drew attention to the potential cardioprotective effects 
of estrogen was that differences associated with female sex disappear in women at the 
postmenopausal stage. In good agreement with the clinical findings, preclinical studies 
have reported that sex differences in hemodynamic overload-induced HF diminish in 
female rats after ovariectomy (99). In contrast, exogenous estrogen administration in 
ovariectomized female rats restores the characteristic sex-related differences in PO-
induced HF (100). Further research has also identified that the regulatory effects of 
estrogen are mainly mediated via the nuclear estrogen receptor β (ER-β) in PO-evoked 
LVH (101-103). The interaction between estrogen and ER-β induces alterations in 
myocardial gene expression, which fundamentally affects the hypertrophied LV 
phenotypes in females. In the following sections, sex-related differences in PO-induced 
LVH are briefly summarized. 
  
2.4.1. Effect of sex on structural alterations  
2.4.1.1. Sex-associated differences in myocardial hypertrophy 
Women with long-lasting AH or AS, as well as female rats with sustained PO are prone 
to develop thicker ventricular walls, smaller LV chamber dimensions and a more 
concentric form of LVH compared to male counterparts (104-109). Recent experiments 
have proposed that the characteristic morphological and geometrical differences might be 




in females during the progression of PO-induced LVH. Accordingly, relatively early after 
PO-induction, concentric LVH is observed in both genders. However, during the 
progression of chronic cardiovascular conditions, continuous cardiac cell loss and ECM 
remodeling takes place in males but not in females, resulting in chamber dilatation and 
eccentric geometry (110, 111). In contrast, female sex and estrogen-mediated signaling 
yield protection against apoptosis and MMP upregulation (111, 112), and prevents 
chamber dilation. 
Recent clinical experiments also aimed at investigating potential sex-related 
discrepancies in the regression of LVH after pressure unloading therapy. Petrov and his 
colleagues found that LV end-diastolic diameter (LVEDD) decreased in female but not 
in male patients 3 days after AVR (111). In contrast, Dobson et al. have reported no sex-
related differences in LV mass regression during a 6-month long follow-up period (76). 
Similarly, Stangl et al. have also observed that reduction of LV mass occurred to a similar 
extent in both genders 3 month after AVR/TAVI (113). In contrast, antihypertensive 
therapies have demonstrated a less efficient regression of LV mass in female patients 
compared to their male counterparts (108, 114). Unfortunately, no animal studies to date 
have been conducted on this field to confirm or contradict the mentioned clinical findings.  
 
2.4.1.2. Sex-associated differences in myocardial fibrosis 
Sex differences in myocardial fibrosis have been widely documented by numerous 
preclinical and clinical investigations during the development of PO-induced LVH. 
Accordingly, examination of endomyocardial biopsies from AS patients have consistently 
revealed more severe collagen accumulation in men compared to women (109, 115). The 
histological findings have been further supported by gene expressional analysis, reporting 
substantially higher mRNA levels of pro-fibrotic genes in LV speciments from male AS 
patients compared to their female counterparts (111). Besides the histological 
examinations, current CMR studies have reported considerable differences in myocardial 
fibrosis between men and women under sustained PO. Importantly, in these particular 
studies, the newly developed CMR imaging modalities have allowed investigators to 
differentiate between replacement and reactive fibrosis. The separate quantification of 
replacement and reactive interstitial fibrosis has revealed that both types of myocardial 




increment in afterload (116). Of particular interest, animal models of LV PO have also 
confirmed that male sex is associated with more maladaptive ECM remodeling under 
standard laboratory conditions (101, 102).  
To date, only a few studies have analyzed the potential influential effect of sex on the 
regression of myocardial fibrosis following pressure unloading. Among them, Dobson et 
al. has reported that myocardial fibrosis regressed only in female but not in male patients 
after AVR during a 6 month long follow-up period (76). However, further preclinical 
research is warranted to test whether female sex is indeed associated with a more plastic 
form of myocardial fibrosis.  
 
2.4.2. Effect of sex on molecular alterations  
The adaptation of the LV to chronic PO seems to differ on the molecular level as well 
between the two genders. Accordingly, in a TAC-induced pathological LVH model, PO 
evoked more severe upregulation of the fetal gene program (β-MHC and ANP) in male 
rats compared to their female counterparts (117). Furthermore, detailed analysis of the 
LV transcriptome has identified specific sex-dependent regulation of gene expression. 
These investigations have revealed that the transcription of genes associated with 
mitochondrial function and fatty acid oxidation were more robustly suppressed in males 
compared to females. In contrast, genes encoded ribosomal proteins and ECM 
components were more intensely upregulated in male rodents compared to female ones 
(118).  
 
2.4.3. Effect of sex on left ventricular function 
2.4.3.1. Sex-associated differences in left ventricular systolic function 
Sex is a major determinant of LV systolic function during the development of PO-
induced LVH. Accordingly, better EF and fractional shortening have been consistently 
reported in female patients with chronic AH or AS compared to male patients (105, 106, 
108, 109, 119). Furthermore, it has been also suggested that females might experience a 
greater improvement in EF after pressure unloading compared to their male counterparts 
(113). Besides the clinical findings, animal models of PO-induced LVH have confirmed 
that following a common compensated stage, deterioration of LV systolic function occurs 




However, a major limitation of the beforementioned clinical and preclinical 
investigations is that none have assessed in vivo LV contractility independently from 
loading conditions.  
 
2.4.3.2. Sex-associated differences in left ventricular diastolic function 
Besides the prominent sex-related differences in LV systolic function, hemodynamic 
characterization of male and female AS patients have indicated that distinct discrepancies 
might exist in diastolic function as well.  
Active relaxation. Villari and his colleagues have observed the prolongation of the 
active relaxation time constant (Tau) in both genders with chronic PO (109). According 
to their findings, deterioration of active ventricular relaxation occurred to an equal extent 
in both men and women.   
Passive filling. In contrast to active relaxation, major differences have been 
documented in passive filling between the two sexes. Correspondingly, impairment of 
myocardial stiffness was only detected in men but not in women patients with AS (109). 
Furthermore, LVEDP was found to be elevated in male rodents, while no significant 
alteration could be detected in LVEDP in their female counterparts (101, 104). Thus, 
clinical and experimental evidence suggests that male sex is associated with a more severe 
impairment of LV passive diastolic properties under sustained PO. This latter functional 
finding is in good agreement with the ultrastructural differences between the two genders, 
with more severe ECM remodeling having been reported in male patients and 




2.5. Animal models of pressure overload-induced remodeling and pressure 
unloading-evoked reverse remodeling 
In the past years, various animal models of PO-induced pathological remodeling have 
been introduced. Among them, aortic constriction-induced PO (by surgically constricting 
the ascending [AAC], the transverse [TAC] or the abdominal [AB] aorta), essential 
hypertension-induced PO (e.g. the SHR strain or the Dahl salt sensitive rat strain), renal 
hypertension-induced PO (e.g. 5/6 nephrectomy) and genetically modified rodent strains 
(e.g. rats overexpressing the mouse renin gene) are the most widely utilized (120-123). 
All of these experimental approaches have proven to be valuable tools in studying the 
temporal development of PO-induced LVH and its progression to symptomatic HF. 
Nevertheless, surgical models have the advantage that the pathological trigger of PO (the 
aortic constriction) can be removed by a second minimal invasive operation. Therefore, 
these models provide a unique opportunity to study not only PO-induced remodeling but 
also pressure unloading-evoked reverse remodeling under standard laboratory conditions. 
Importantly, prior investigation utilizing AB and debanding rodent models have reported 
that these experimental approaches reliably recapitulate those alterations that occur in 
human patients after pressure unloading therapy (68, 70, 80, 83, 88, 89, 92, 124-128). 
Hence, these particular animal models could indeed serve as an adequate tool to address 
those scientific questions regarding myocardial reverse remodeling that cannot be 






A considerable body of clinical evidence has accumulated to support the notion that in 
case of PO-induced HF, termination of the pathological stimulus (by antihypertensive 
medications in case of AH or AVR/TAVI in case of AS) could results in a state of reverse 
remodeling with substantial improvement in LV structure and function. Nevertheless, it 
has been also recognized that not all the patients experience the same extent of functional 
and structural improvement following pressure unloading therapy. Hence, efforts have 
been taken to identify factors which might influence the regression of LVH. These recent 
studies have raised the possibility that the time point of medical interventions (performing 
pressure unloading at early versus late stages of PO-induced LVH) and the sex of the 
patients might determine the success of the reverse remodeling process (70, 76, 92, 111). 
Considering that many confounding factors (differences in comorbidities, age and 
medications) can limit the overall impact of the clinical observations, further 
experimental studies utilizing animal models are warranted.  
 
Based upon that, the aims of the present studies were: 
 
1. To establish a rat model of mechanical PO-induced pathological remodeling and 
pressure unloading-evoked reverse remodeling with microsurgical techniques. 
 
2. To explore timeline alterations in LV structure and function during the development 
of PO-induced LVH and its progression to HF in male rats. 
 
3. To investigate the effects of myocardial reverse remodeling from early versus late 
stages of PO-induced LVH in male rats. 
 
4. To study the effect of sex on different aspects of LV structure and function during 







The investigation conformed to the EU Directive 2010/63/EU and the Guide for the 
Care and Use of Laboratory Animals used by the US National Institutes of Health (NIH 
Publication No.85–23, revised 1996). The experiments were approved by the ethics 
committee of the Land Baden-Württemberg for Animal Experimentation (G-94/15 and 
G-198/16). The studies were interpreted in accordance with the ARRIVE (Animals in 
Research: Reporting in Vivo Experiments) guidelines (129). The animals were kept under 
standard conditions (22±2ºC with 12h light/dark cycles) and were allowed access to 
laboratory rat diet and water ad libitum during the whole experimental period. Before 
performing any type of surgeries, the rats underwent a one-week long acclimatization 
period.   
 
4.2. Animal models  
4.2.1. Rat model of pressure overload-induced myocardial remodeling 
In order to induce PO of the LV, the previously described method of AB was 
established in our laboratory with slight modifications (61). In brief, the surgery consisted 
of the following steps. General anesthesia was induced in male and female Sprague-
Dawley rats (5-6 weeks-old; 160-180g; Janvier, France) with 5% of isoflurane gas in a 
chamber and maintained by inhalation from a connected tube with 1.5–2% of isoflurane 
in O2. The animals were placed in a supine position on an automatic heating pad to 
maintain the core temperature at 37°C, measured via a rectal probe. The abdominal hair 
was removed and an antiseptic solution was applied to disinfect the skin on the surgical 
area. The surgery was performed in midline laparotomy under sterile conditions. After 
the intestinal tract was gently placed aside, the peritoneal layer was dissected in order to 
gain access to the retroperitoneal space. The abdominal aorta between the right renal 
artery and the superior mesenteric artery was carefully cleaned from the surrounding 
connective tissue. A blunted 22-gauge needle was utilized to constrict the aorta above the 
right renal artery. After AB was completed, the intestines were placed back to the 
abdominal cavity and the abdominal muscle layer was sutured in single interrupted 




analgesia was provided by subcutaneously administered buprenorphine in the dose of 
0.05mg/kg. Furthermore, 1ml physiological saline was also applied subcutaneously to 
avoid post-operative hypovolemia. Sham-operated animals were subjected to the same 
surgical procedure, except the aortic constriction (n=28). 
 
 
Figure 3. Abdominal aortic banding. Photos were taken at different phases during the surgical 
procedure of abdominal aortic banding. Phase 1: After a midline laparotomy, the intestines were 
taken aside and the peritoneal layer was visualized. Phase 2: By dissecting the peritoneal layer 
the abdominal aorta was identified. Phase 3: A 2.0 silk suture was placed around the abdominal 
aorta at the suprarenal level. Phase 4: A blunted 22-gauge needle was taken between the anterior 
surface of the aorta and the ligature. Phase 5: The ligature around both the needle and the aorta 
was tied. Finally, the needle was carefully removed, leaving a constriction on the abdominal aorta 
with a size of the external diameter of a 22-gauge needle.  
 
4.2.2. Rat model of pressure unloading-induced reverse myocardial remodeling 
After 6 weeks of AB (early debanding) or 12 weeks of AB (late debanding) a group of 
animals underwent a second minimal invasive surgery, when the aortic constriction was 
removed from the abdominal aorta (debanding). During this second surgery, general 
anesthesia was provided by isoflurane inhalation (5% for induction of anesthesia and 2-
3% for maintenance of anesthesia). Rats were placed on a heating pad in a supine position. 




antiseptic solution. A midline laparotomy was performed in the line of the scar from the 
previous surgery. The intestines were then localized in a way, that their position allowed 
us to visualize the abdominal aorta. The previously placed aortic constriction was 
identified and it was cleaned from the surrounding fibrotic tissue. The narrowing suture 
was carefully cut and removed from the abdominal aorta. The abdominal muscle and the 
skin layer were sutured in the single interrupted fashion. To prevent postoperative pain 
and dehydration, buprenorphine (in the dose of 0.05mg/kg) and physiological saline 
(1.5ml) was injected subcutaneously before the animals regained awareness.  
 
4.3. Study protocols 
The study protocols are summarized in Figure 4, Figure 5 and Figure 6.  
 
4.3.1. Study 1: Longitudinal assessment of pressure overload-induced structural 
and functional alterations of the left ventricle in male rats 
In the AB model, LV PO is evoked to a moderate level, which results in a relatively 
slow disease progression. Based on previous literature data, the time points of week 6, 12 
and 18 were chosen to detect characteristic alterations at early and advanced stages of 
PO-induced HF. Accordingly, after AB or sham operations, the rats were randomized into 
the following 6 experimental groups:  
Sham-wk6 group (n=9): after sham operation the rats were followed-up for 6 weeks; 
AB-wk6 group (n=13): after AB the rats were followed-up for 6 weeks; 
Sham-wk12 group (n=9): after sham operation the rats were followed-up for 12 weeks; 
AB-wk12 group (n=13): after AB the rats were followed-up for 12 weeks; 
Sham-wk18 group (n=10): after sham operation the rats were followed-up for 18 weeks; 





Figure 4. Schematic illustration of the experimental protocol of Study 1. At baseline, the rats 
underwent abdominal aortic banding ([AB]; n=39) or sham operation (n=28) and were 
subsequently randomized into 6 groups. In the Sham-wk6 (n=9) and AB-wk6 (n=13) groups, 
pressure-volume (P-V) analysis and tissue collection were performed 6 weeks after AB/sham 
operations. In the Sham-wk12 (n=9) and AB-w12 (n=13) groups, P-V analysis and tissue 
collection were performed 12 weeks after AB/sham operations. In the Sham-wk18 (n=10) and AB-
w18 (n=13) groups, P-V analysis and tissue collection were performed 18 weeks after AB/sham 
operations. Furthermore, repetitive echocardiographic measurements at baseline, week 3, 6, 9, 12, 
15 and 18 were also carried out in the Sham-wk18 and AB-wk18 groups. 
 
4.3.2. Study 2: Investigating the effects of myocardial reverse remodeling from 
early- versus late-stage left ventricular hypertrophy in male rats 
Similar to Study 1, the AB model was utilized to induce different stages of PO-induced 
LVH in Study 2 as well. However, in this investigation two additional groups were 
introduced to study the regression of LVH from early and late stages of LVH. In these 
experimental groups, a second minimal invasive surgery was performed to remove the 
aortic constriction at week 6 (early debanded) and week 12 (late debanded). Both 
debanded groups were followed up for 6 weeks. Accordingly, Study 2 consisted of the 
following 8 groups:  
Sham-wk6 group (n=10): after sham operation the rats were followed-up for 6 weeks; 
AB-wk6 group (n=10): after AB the rats were followed-up for 6 weeks; 




AB-wk12 group (n=11): after AB the rats were followed-up for 12 weeks; 
Sham-wk18 group (n=9): after sham operation the rats were followed-up for 18 weeks; 
AB-wk18 group (n=13): after AB the rats were followed-up for 18 weeks, respectively. 
Early debanded group (n=14); these rats underwent AB operation, after week 6 the 
banding suture was removed and the rats were followed up until week 12;  
Late debanded group (n=15): these rats underwent AB operation, after week 12 the 
banding suture was removed and the rats were followed up until week 18.  
 
Figure 5. Schematic illustration of the experimental protocol of Study 2. At baseline, the rats 
underwent abdominal aortic banding ([AB]; n=63) or sham operation (n=29) and were 
subsequently randomized into 8 groups. The Sham-wk6 (n=10), AB-wk6 (n=10) groups were 
followed-up for 6 weeks. The Sham-wk12 (n=10), AB-wk12 (n=11) groups were followed-up for 
12 weeks, while the Sham-wk18 (n=9), AB-wk18 (n=13) were followed-up for 18 weeks. In the 
early debanded group (n=14) the aortic constriction was removed after week 6, while in the late 






4.3.3. Study 3: Investigation of sex differences during the development of pressure 
overload-induced left ventricular hypertrophy. 
In this particular study, male and female rats underwent AB to investigate sex-related 
differences in the adaptation to chronic PO. Age- and sex-matched sham operated animals 
served as controls. Considering that sex differences were suggested to develop by time, 
functional and structural characterization of PO-induced LVH was carried out at a 
relatively early (week 6) and late (week 12) time points as well after PO induction. 
Accordingly, the following experimental groups were used in Study 3:  
Male sham-week6 group (n=8): male rats underwent sham operation and were followed-
up for 6 weeks 
Male AB-week6 group (n=8): male rats underwent AB and were followed-up for 6 weeks;  
Female sham-week 6 group: female rats underwent sham operation and were followed-
up for 6 weeks 
Female AB week 6 group (n=7): female rats underwent AB and were followed-up for 6 
weeks;  
Male sham week 12 group (n=8): male rats underwent sham operation and were followed-
up for 12 weeks;  
Male AB week 12 group (n=10): male rats underwent AB and were followed-up for 12 
weeks;  
Female sham week 12 group (n=8): female rats underwent sham operation and were 
followed-up for 12 weeks;  






Figure 6. Schematic illustration of the experimental protocol of Study 3. At baseline, male and 
female rats underwent abdominal aortic banding ([AB]; n=32) or sham operation (n=32) and were 
subsequently randomized into 8 groups. In the male sham-wk6 (n=8) and AB-wk6 (n=8) groups 
and female sham-wk6 (n=8) and AB-wk6 (n=7) groups pressure-volume (P-V) analysis and tissue 
collection were performed at week 6. In the male sham-wk12 (n=8) and AB-wk12 (n=10) groups 
and female sham-wk12 (n=8) and AB-wk12 (n=7) groups pressure-volume (P-V) analysis and 
tissue collection were performed at week 12. Furthermore, repetitive echocardiographic 
measurements were performed in the male and female sham-wk12 and AB-wk12 groups. 
 
4.4. Echocardiography 
Echocardiography was carried out to characterize the morphological alterations during 
PO-induced pathological remodeling and pressure unloading-evoked reverse remodeling. 
For the sonographic measurements the Vevo® 2100 imaging system (Fujifilm Visual 
Sonics Inc., Toronto, Ontario, Canada) equipped with a 21-MHz linear probe was 
utilized. Repetitive measurements were performed at baseline and at week 3, 6, 9, 12, 15 
and 18. During the echocardiographic measurements the following protocol was utilized. 
General anesthesia was induced by isoflurane. The rats were placed on an automatic 
heating pad in a supine position to maintain the body temperature of the animals at 37°C. 




two dimensional parasternal long-axis and short-axis views as well as M-mode recordings 
at the mid-papillary level were taken. Digital images were analyzed in a blinded fashion. 
LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), anterior wall 
thickness (AWT) and posterior wall thickness (PWT) in diastole (d) and systole (s) were 
measured. All values were calculated as an average of three consecutive cardiac cycles. 
Furthermore, from the measured parameters, EF, relative wall thickness 
([RWT]=[AWTd+PWTd]/LVEDD), LV mass (according to the Devereux formula) (130), 
and its index to the body weight (LV mass index) were calculated.  
 
4.5. Pressure-volume analysis 
At the end of the experimental period (at week 6, 12 or 18, respectively) the rats were 
anaesthetized by inhalation of 5% isoflurane gas in a chamber. After anesthesia was 
induced, the rats were placed in a supine position on an automatic heating pad to keep the 
core temperature at 37°C. To maintain anesthesia during the whole hemodynamic 
measurement, the rats were tracheotomized, intubated and artificially ventilated with 1-
1.5% isoflurane gas in 100% O2. Rocuronium bromide in the dose of 2mg/kg was 
administered intraperitoneal to induce muscle relaxation. A polyethylene catheter was 
inserted into the left external jugular vein for fluid administration. A 2F microtip pressure-
conductance catheter (SPR-838, Millar Instruments, Houston, Texas, USA) was inserted 
into the right carotid artery and subsequently advanced into the ascending aorta. 
Following stabilization, arterial blood pressure was recorded. The catheter was then 
guided to the LV under pressure control. With the use of a special P-V analysis program 
(PVAN, Millar Instruments, Houston, TX, USA) systolic arterial blood pressure (SBP), 
diastolic arterial blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), 
LV end-systolic pressure (LVESP), LV end-diastolic pressure (LVEDP), maximal slope 
of systolic pressure increment (dP/dtmax) and diastolic pressure decrement (dP/dtmin), LV 
end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), stroke volume (SV), 
cardiac output (CO), EF, arterial elastance (Ea; calculated by the following equation 
Ea=LVESP/SV (131)), and time constant of LV pressure decay (Tau; according to the 
Glanz method (132)) were computed and calculated.  
In order to detect load-independent contractility parameters, P-V loops were also 




the inferior caval vein. The slope of the end-systolic P-V relationship (ESPVR, according 
to the parabolic curvilinear model (133)) and preload recruitable stroke work (PRSW) 
and the slope of the dP/dtmax-end-diastolic volume relationship (dP/dtmax-EDV) were 
calculated as reliable indices of LV contractility.  
To characterize myocardial compliance, the slope of the end-diastolic P-V relationship 
(EDPVR) was calculated. 
Furthermore, ventriculo-arterial coupling (VAC) was also assessed as the ratio of Ea 
and ESPVR (VAC= Ea/ESPVR). 
From the hemodynamic and echocardiographic measurements, LV meridional wall 
stress (σ) was estimated by the following equation σ= 
0.334*LVESP*[LVDs/(1+PWTs/LVDs)] (104). 
Parallel conductance was calculated and volume calibration of the conductance system 
was performed as previously described (52).  
 
4.6. Morphometry and tissue conservation 
Following P-V analysis, the infrarenal part of the abdominal aorta was cannulated and 
the blood of the animals was subsequently collected. To remove the residual blood cells 
from myocardial tissue, retrograde perfusion from the abdominal aorta was applied with 
50ml oxygenated, physiological saline. After perfusion, the heart of the animals was 
removed from the thorax and their weights were quickly measured on a scale. This was 
followed by conservation of LV myocardial tissue. Accordingly, transverse segments (the 
middle third part) of the right and the left ventricles were fixed in buffered 
paraformaldehyde solution (4%; for 24 hours) followed by 70% alcohol. The fixed 
samples were than embedded in paraffin for histological analysis. Furthermore, the apex 
of the LV was cut into small pieces (40-50mg) and subsequently snap frozen in liquid 
nitrogen. The collected samples were stored at -80°C until molecular measurements 
(qRT-polymerase chain reaction [PCR] or Western blot) were performed. After tissue 
conservation was accomplished, tibial length (TL) was measured and the ratio of heart 





4.7. Left ventricular histology 
Transverse, transmural, 5-µm thick slices of the paraffin-embedded heart samples 
were cut and placed on adhesive slides. These sections were subsequently stained with 
hematoxylin and eosin staining to determine cardiomyocyte diameter (CD) as a cellular 
marker of myocardial hypertrophy. In each sample, 100 longitudinally oriented 
cardiomyocytes from the LV were examined, and their diameters at transnuclear positions 
were defined with ImageJ software (National Institutes of Health, Bethesda, MD, USA). 
The mean value of 100 measurements represented one sample.  
The extent of myocardial fibrosis was assessed on picrosirius-stained sections. ImageJ 
software was used to identify the picrosirius-red positive area. Six images (magnification 
50X) were randomly taken from the free LV wall on each section. After background 
subtraction, eye controlled auto-threshold has been determined to detect positive areas. 
The collagen area (picrosirius red positive area-to-total area ratio) was determined on 
each image, and the mean value of six images represents each animal. Furthermore, 
perivascular fibrosis was assessed by the percentage of perivascular collagen area to total 
vascular area. The extent of perivascular fibrosis was also assessed by using ImageJ 
software.  
The evaluation of the histological sections was performed by an independent observer 
who was blinded to the experimental design. 
 
4.8. Left ventricular gene expression analysis 
LV myocardial samples stored at -80°C were homogenized (Precellys Evolution tissue 
homogenizer, Bertin Instruments, Montigny-le-Bretonneux, France) in a lysis buffer 
(RLT buffer; Qiagen, Hilden, Germany). During tissue homogenization, the temperature 
of the samples was maintained at 0°C by using the Cryolis Evolution cooling system 
(Bertin Instruments). RNA was isolated using the RNeasy Fibrous Tissue Mini Kit 
(Qiagen), according to the manufacturer’s instructions. The quality and concentration of 
the isolated RNA were assessed by the NanoDrop 2000 Spectrophotometer (Thermo 
Scientific, Waltham, MA, USA). Accordingly, optical density at 230, 260, and 280 nm 
was measured. The ratios of 230/260 and 230/280 nm were defined for quality control. 
Reverse transcription reaction (1µg total RNA of each sample) was completed using the 




Quantitative real-time PCR was performed either with the StepOnePlus Real-Time 
PCR System (Applied Biosystems, Foster City, CA, USA) in duplicates (in Study 1) or 
with the LightCycler 480 System (Roche, Mannheim, Germany) in duplicates (in Study 
2 and 3). The reaction mixture for the measurement with StepOnePlus Real-Time PCR 
System contained 1µl sample cDNA, 5µl TaqMan Universal PCR MasterMix (Applied 
Biosystems), 0.5µl TaqMan Gene Expression Assay (Applied Biosystems) (the assay 
identification numbers are shown in Table 1) and 3.5µl RNA-free water (Qiagen).The 
reaction mixture for the measurement with the LightCycler 480 System consisted of 2µl 
sample cDNA, 0.2µl forward primer (TIB Molbiol, Berlin, Germany), 0.2µl reverse 
primer (TIB Molbiol), 0.2µl Universal Probe Library (UPL) probe (Roche) (the 
sequences of forward and reverse primers and the identification numbers of the UPL 
probes are shown in Table 2), 10µl LightCycler 480 Probes Master (Roche) and 7.4µl 
RNA-free water (Qiagen).  
Gene expression data was normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), and expression levels were calculated using the CT comparative method (2-
ΔCT). All results are expressed as values normalized to a positive calibrator (a pool of 
cDNA from all samples of the Sham-wk6 group in Study 1 and 2 and the Male-Sham-
wk6 group in Study 3 [2-ΔΔCT]). 
Table 1. The full names and the abbreviations of the measured target genes and the identification 
numbers of TaqMan® Gene Expression Assays are shown.  





Expression Assay ID 
Fetal gene 
program 
myosin heavy chain-α α-MHC Rn00568304_m1 
myosin heavy chain-β β-MHC Rn00568328_m1 
atrial natriuretic peptide ANP Rn00664637_g1 
Pro-fibrotic 
mediator 












Table 2. The full names and the abbreviations of the measured target genes, the sequences for 
forward (F) and (R) reverse primers and the identification numbers of Universal Probe Library 
(UPL) probes are shown. 















































4.9. Left ventricular protein expression analysis 
Western blot measurement was performed to detect alterations in the myocardial 
protein expression of CTGF. Fresh-frozen LV samples were homogenized in RIPA buffer 
(Sigma Aldrich, St. Louis, Missouri, USA) containing Complete Protease Inhibitor 
Cocktail (Roche) and PhosSTOPTM phosphatase inhibitor coctail (Roche) at 0°C. Tissue 
homogenization was carried out by using Precellys Evolution homogenizer equipped with 
the Cryolis Evolution cooling system. The tissue lysates were agitated at 4°C for 1 hour. 




supernatant was collected. Protein concentration was measured by Pierce BCA Protein 
Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA). Samples were mixed with 2X 
Laemmli Sample Buffer (Sigma Aldrich) containing reducing agent and subsequently 
boiled at 95°C for 5min. An equal amount of protein (20µg) was loaded onto a 
commercially available precast 4–12% sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis gel (NuPAGE® Novex® Bis-Tris Mini Gel, Invitrogen, Carlsbad, CA, 
USA) and separated by gel electrophoresis (using PowerEase 500 electrophoresis power 
supply [Invitrogen], and applying 90mV for 30min and 120mV for 60min). Transfer of 
the separated proteins to a polyvinylidene fluoride membrane was carried out under dry 
conditions by using an electroblotting system (iBlot™ Gel Transfer Device, Invitrogen). 
After transfer, the membranes were washed and blocked for 1h in 5% of BSA in Tris-
buffered saline-Tween 20 at room temperature to reduce the nonspecific bindings of 
antibodies. The membranes were then incubated overnight at 4°C with the primary 
antibody. The blots were washed to remove excessive primary antibody binding and 
incubated with horseradish peroxidase-conjugated secondary antibodies for 1h at room 
temperature (anti-rabbit IgG, Cell Signaling Technology, Danvers, MA, USA). GAPDH 
housekeeping protein was used as loading control and protein normalization.  Blots were 
developed by the enhanced chemiluminescence detection assay (SuperSignalTM West 
Pico PLUS Chemilumiescent Substrate, Thermo Fisher Scientific) and the intensity of the 
bands was measured by the ChemiDocTM Touch Imaging system (Bio-Rad, Hercules, CA, 
USA).  
Table 3. The full names and the abbreviations of the measured target proteins, the code of the 






























4.10. Statistical analysis  
4.10.1. Study 1 
 All values are expressed as mean±standard error of the mean. The distribution of the 
datasets was tested by D’Agostino-Pearson omnibus test (when number of measurements 
reached 8 in a group) or by Shapiro-Wilk normality test (when number of measurements 
failed to reach 8 in a group). 
An unpaired two-sided Student’s t-test in case of normal distribution or Mann-Whitney 
U test in case of non-normal distribution was used to compare the echocardiographic 
parameters between the Sham-wk18 and the AB-wk18 groups at baseline, and at week 3, 
6, 9, 12, 15 and 18. Repeated-measures one-way analysis of variance (ANOVA) or 
Friedman test was performed for comparing data of the echocardiographic measurements 
at different time points (week 3, 6, 9, 12, 15 and 18) within a group. To examine 
intergroup differences, Holm-Sidak or Dunn post hoc test was carried out. 
Two-way ANOVA with the factors “time” and “AB” were carried out to compare 
six independent groups in all the other measurements. Prior to two-way ANOVA, those 
datasets that failed to show normal distribution were logarithmically transformed. Tukey 
post hoc test was utilized to detect intergroup differences. 
A P value of <0.05 was used as a criterion for statistical difference. Furthermore, 
two additional categories (P<0.01 and P<0.001) were introduced to indicate the strength 
of the observed statistical difference. 
 
4.10.2. Study 2 
All values are expressed as mean±standard error of the mean. The distribution of the 
datasets was tested by D’Agostino-Pearson omnibus test (when number of measurements 
reached 8 in a group) or by Kolmogorov-Smirnov test (in case of Western blot 
measurements, when number of samples were 6 per group). 
An unpaired two-sided Student’s t-test in case of normal distribution or Mann-Whitney 
U test in case of non-normal distribution was used to compare two independent groups. 
One-way ANOVA followed by Tukey’s post hoc test or Kruskal-Wallis test followed by 
Dunn’s post hoc test was carried out to compare three independent groups.   
When data was available (in case of repeatable, non-invasive measurements: 




debanding: week 6 in case of early debanded and week 12 in case of late debanded) and 
at the end of the experimental period (post-debanding: week 12 in case of early debanded 
and week 18 in case of late debanded) a ratio of post-debanding/pre-debanding values 
was calculated. These values were used to directly compare the extent of regression 
between the early and the late debanded groups. 
When repetitive data was not available (in case of not repeatable measurements: 
postmortem organ measurements, P-V analysis, histology and PCR) from the same 
animal, individual data were normalized to the mean value of the corresponding sham 
groups. These normalized values were used to compare hypertrophy-associated 
alterations among the AB groups (AB-6wk, AB-12wk, AB-18wk groups) and between 
the debanded groups (early and late debanded), respectively.  
A P value of <0.05 was used as a criterion for statistical difference. 
 
4.10.3. Study 3 
All values are expressed as mean±standard error of the mean. The distribution of the 
datasets was tested by Shapiro-Wilk normality test.  
Two-way ANOVA with the factors “time” and “AB” was utilized to compare the four 
male (Sham/AB 6 week and Sham/AB 12 week groups) and the four female (Sham/AB 
6 week and Sham/AB 12 week groups) groups separately. Prior to two-way ANOVA, 
those datasets that failed to show normal distribution were logarithmically transformed.  
To directly compare hypertrophy-associated alterations between the two genders, 
individual data of the AB groups were normalized to the mean value of the corresponding 
sham groups. An unpaired two-sided Student’s t-test in case of normal distribution or 
Mann-Whitney U test in case of non-normal distribution was used to compare the 
hypertrophy-associated changes in each parameter.  
In case of echocardiographic measurements, two-way ANOVA with the factors “sex” 
and “AB” was performed to compare four groups (male/female Sham and male/female 
AB groups) at five different time points (baseline, week 3, week 6, week 9 and week 12). 





Spearman correlation test was performed to detect correlations between LV mass 
index and Tau, between collagen area and LVEDP and between collagen area and 
EDPVR. 







5.1. Longitudinal assessment of pressure overload-induced structural and 
functional alterations of the left ventricle 
5.1.1. Echocardiography 
From week 3 until the end of the experimental period, AWTd, PWTd and LVmassindex 
were increased in the AB-wk18 group compared to the sham-wk18 group, indicating the 
development of LVH (Fig. 7 and Fig. 8A-C). Furthermore, at week 12, week 15 and 
week 18, LVEDD was also increased in the AB-wk18 group compared to the sham-wk18 
group, suggesting chamber dilatation (Fig. 8D). 
 
Figure 7. Representative echocardiographic recordings. Representative M-mode 
echocardiographic recordings at the midpapillary muscle level are shown in the sham and the 
aortic banded groups at week 6, 12 and 18. AWTd: anterior wall thickness in diastole, AWTs: 
anterior wall thickness in systole, LVESD: left ventricular end-systolic diameter, LVEDD: left 
ventricular end-diastolic diameter, PWTd: posterior wall thickness in diastole, PWTs: posterior 






Figure 8. Echocardiographic follow-up during the development of pressure overload-induced 
myocardial hypertrophy. Anterior (A) and posterior (B) wall thicknesses as well as left 
ventricular (LV) mass index (LVmassindex) (C) were already increased after 3 weeks of LV 
pressure overload in the aortic banded groups. Furthermore, the aortic banded group was also 
associated with elevated LV end-diastolic diameter (LVEDD) (D) after 12 weeks of pressure 
overload. AWTd: anterior wall thickness in diastole, PWTd: posterior wall thickness in diastole *: 
P<0.05 vs. corresponding sham. **: P<0.01 vs. corresponding sham. ***: P<0.001 vs. 
corresponding sham. †: P<0.05 vs. week 3. ‡: P<0.05 vs. week 6. #: P<0.05 vs. week 9. 
 
5.1.2. Pathological hypertrophy and fibrosis markers  
In the AB-wk6, AB-wk12 and AB-wk18 groups, HW/TL and CD were increased 
compared to the corresponding sham groups (Fig. 9). The myocardial mRNA expression 
levels of β/α-MHC ratio and ANP were also elevated in the AB groups compared to their 
corresponding sham groups, indicating reactivation of the fetal gene program (Fig. 10).  




fibrosis in the AB-wk12 and AB-wk18 groups compared to the sham-wk12 and sham-
wk18 groups, respectively (Fig. 11). 
 
Figure 9. Macroscopic and microscopic myocardial hypertrophy markers. Representative 
photomicrographs (A) of hematoxylin and eosin staining (magnification 200x, scale bar: 40µm) 
are shown demonstrating enlarged cardiomyocytes in the aortic banded groups. Cardiomyocyte 
diameter (CD) (B) and heart weight-to-tibial length (HW/TL) (C) increased in the aortic banded 
groups at week 6, 12 and 18 compared to sham groups. ***: P<0.001 vs. corresponding sham. 
 
 
Figure 10. Fetal gene expression during pressure overload-induced myocardial hypertrophy. 
mRNA expression of beta-to-alpha myosin heavy chain (β/α-MHC) (A) and atrial natriuretic 
peptide (ANP) (B) increased in the aortic banded groups at week 6, 12 and 18 compared to the 





Figure 11. Interstitial fibrosis. Representative photomicrographs of picrosirius red staining 
(magnification 50x, scale bar: 200µm) (A) are shown demonstrating increased interstitial fibrosis 
in the aortic banded groups at week 12 and week 18. Quantification of the collagen area (B) 
confirmed increased collagen accumulation in the aortic banded groups at week 12 and 18 
compared to the age-matched sham groups. *: P<0.05 vs. corresponding sham. **: P<0. 01 vs. 
corresponding sham. 
 
5.1.3. Left ventricular function 
 
5.1.3.1. Arterial loading 
SBP, DBP and MAP were elevated in the AB groups compared to the corresponding 
sham groups, confirming the presence of increased PO proximal to the aortic constriction 
(Table 4).  
 
5.1.3.2. Load-dependent systolic parameters 
The AB-wk6 group was associated with preserved systolic performance. Accordingly, 
no difference could be observed in load-dependent systolic parameters (EF, SV, CO) 
between the AB and the sham group at week 6 (Fig. 12, Table 4). In contrast, in the AB-
wk12 and AB-wk18 groups, EF decreased significantly, while SV and CO showed a 






Figure 12. Representative steady-state pressure-volume (P-V) loops are shown 
demonstrating in vivo left ventricular (LV) function in sham and aortic banded (AB) rats 
at different time points. The width of the P-V loops in the AB group at week 6 does not differ 
from the control’s width. In contrast, at week 12 and 18, the width of the loops becomes 
substantially smaller in the AB groups, suggesting impaired systolic performance. Furthermore, 






Table 4. Steady state functional parameters in aortic banded and sham-operated rats at different time points. Values are expressed as mean ± standard 
error of the mean. AB indicates aortic banding; SBP: systolic arterial blood pressure; DBP: diastolic arterial blood pressure; MAP: mean arterial pressure; 
HR: heart rate; LVEDV: LV end-diastolic volume; LVESV: LV end-systolic volume; SV: stroke volume; CO: cardiac output; EF: ejection fraction. **: 
P<0.01 vs. age-matched sham. ***: P<0.001 vs. age-matched sham. ##: P<0.01 vs. AB-week 6. ###: P<0.001 AB-week 6. $: P<0.05 vs. AB-week 12. 
$$: P<0.01 vs. AB-week 12. 













SBP, mmHg 148±4 215±4*** 138±5 215±5*** 150±5 228±4*** 
DBP, mmHg 116±3 150±2*** 110±4 154±4*** 120±4 170±3***###$$ 
MAP, mmHg 127±4 172±2*** 119±4 174±4*** 140±4 189±3***##$ 
HR, beats/min 355±7 369±9 354±5 366±7 379±7 357±5 
LVEDV, µl 268±16 305±14 286±23 320±20 283±18 327±14 
LVESV, µl 175±15 194±12 178±17 231±11 160±11 241±11*** 
SV, µl 188±16 173±10 195±11 163±12 175±10 151±15 
CO, ml/min 66.7±6.1 62.9±3.0 69.4±4.5 59.4±4.1 66.3±4.4 53.7±5.4 






5.1.3.3. Load-independent contractility parameters  
In the AB-wk6 group, ESPVR, PRSW and dP/dtmax-EDV increased significantly 
compared to the sham-wk6 group, indicating increased LV contractility (Fig. 13-16). This 
contractility augmentation diminished in the AB-wk12 and AB-wk18 groups (Fig. 13-
16). Accordingly, the load-independent contractility parameters were not different in the 
AB-wk12 and AB-wk18 groups compared to sham-wk12 and sham-wk18 groups, but 
ESPVR and PRSW were significantly decreased compared to the AB-wk6 group (Fig. 
16).  
 
Figure 13. Representative pressure-volume loops in the aortic banded and the sham groups at 
different time points. Original recordings were obtained at different preloads during transient 
vena cava occlusion. At week 6, the slope of the end-systolic P-V relationship (ESPVR) was 
steeper in the aortic banded (AB) group, suggesting enhanced LV contractility. In contrast, the 
slope of the of the end-systolic P-V relationship (ESPVR) did not differ in the aortic banded (AB) 





Figure 14. Alterations in preload recruitable stroke work (PRSW) during the progression of 
pressure overload-induced myocardial hypertrophy. PRSW indicated increased left ventricular 
(LV) contractility in the aortic banded (AB) group at week 6 compared to the corresponding sham 





Figure 15. Alterations in the slope of the maximal systolic pressure increment (dP/dtmax)-end 
diastolic volume (EDV) relationship during the progression of pressure overload-induced 
myocardial hypertrophy. dP/dtmax-EDV indicated augmented left ventricular (LV) contractility 
in the aortic banded (AB) group at week 6 compared to the corresponding sham group. The 





Figure 16. Left ventricular contractility parameters during the development and progression 
of pressure overload-induced left ventricular myocardial hypertrophy. Both the slope of the end-
systolic pressure-volume relationship (ESPVR) (A), preload recruitable stroke work (PRSW) (B) 
and the slope of the maximal systolic pressure increment (dP/dtmax)-end diastolic volume (EDV) 
relationship (C) were increased in the aortic banded (AB) group at week 6 compared to the 
corresponding sham group, suggesting enhanced left ventricular contractility. This contractility 





5.1.3.4. Ventricular-arterial coupling 
In the AB-wk6 group, the enhanced LV contractility (increased ESPVR) (Fig. 13 and 
Fig. 16) counterbalanced the elevated afterload (increased Ea) (Table 5), therefore VAC 
did not differ from the corresponding sham group (Table 5). In contrast, in the AB-wk12 
and AB-wk18 groups, the lack of compensatory LV contractility augmentation (reduced 
ESPVR values compared to AB-wk6) along with the elevated afterload (increased Ea) 
resulted in contractility-afterload mismatch. Thus, the values of VAC were significantly 
higher in the AB-wk12 and AB-wk18 groups compared to that of the AB-wk6 group 
(Table 5). 
 
5.1.3.5. Diastolic parameters 
Tau significantly increased in the AB-wk6, AB-wk12 and AB-wk18 groups compared 
to their corresponding sham groups (Table 5). Furthermore, the slope of EDPVR was 





Table 5. Arterial elastance, ventriculo-arterial coupling and indices of diastolic function in aortic banded and sham-operated rats at different time 
points. Values are expressed as mean ± standard error of the mean. AB indicates aortic banding; Ea: arterial elastance, VAC: ventriculo-arterial coupling 
Tau: time constant of LV pressure decay according to the Glantz’ method; EDPVR: end-diastolic pressure-volume relationship; *: P<0.05 vs. age-matched 
sham. **: P<0.01 vs. age-matched sham. ***: P<0.001 vs. age-matched sham. #: P<0.05 vs. AB-week 6. ##: P<0.01 vs. AB-week 6. ###: P<0.001 AB-
week 6.  













Ea, mmHg/µl 0.75±0.06 1.20±0.08* 0.68±0.05 1.33±0.10*** 0.84±0.05 1.54±0.16*** 
VAC 0.50±0.08 0.45±0.06 0.54±0.06 0.76±0.08## 0.57±0.10 0.87±0.08### 
Tau, ms 14.2±0.4 18.4±0.9** 12.8±0.6 19.4±0. 6*** 13.0±0.3 21.7±1.2***# 






5.2. Investigating the effects of myocardial reverse remodeling from early- versus 
late-stage left ventricular hypertrophy in male rats 
5.2.1. Effect of early and late debanding on echocardiographic parameters 
In the AB groups, sustained PO led to continuous increment in LV mass, AWTd and 
PWTd (Fig. 17-18). Both early and late debanding resulted in significant regression of 
the previously increased LV mass, AWTd and PWTd (Fig. 17-18). To assess the extent 
of hypertrophy regression in the early- and in the late debanded groups, a ratio was 
calculated from the parameters measured at the post-debanding and the pre-debanding 
state. These calculated values were used to compare the effectiveness of reverse 
remodeling between the early and the late debanded groups. No difference was found in 
the extent of LV mass (Fig. 19A), AWTd (Fig. 19B) and PWTd (Fig. 19C) regression 
between the early and late debanded groups.  
 
Figure 17. Representative echocardiographic images during the development of pressure 
overload-induced left ventricular myocardial hypertrophy and its regression after early and late 
debanding. Characteristic M-mode echocardiographic recordings at the midpapillary muscle 
level are shown at week 12 (in case of early debanding) and at week 18 (in case of late debanding) 
in the sham, the aortic banded (AB) and the debanded groups. Myocardial hypertrophy effectively 
regressed after early and late debanding as well. AWT: anterior wall thickness, PWT: posterior 
wall thickness, LVEDD: left ventricular (LV) end-diastolic diameter, LVESD: LV end-systolic 





   
Figure 18. Echocardiographic follow-up during myocardial reverse remodeling from early- 
and late-stage of pathological myocardial hypertrophy. Both in the early and in the late debanded 
groups, left ventricular (LV) mass (LVmass) (A, D), anterior wall thickness measured in diastole 
(AWTd) (B, E) and posterior wall thickness measured in diastole (PWTd) (C, F) effectively 
regressed after pressure unloading. AB indicates aortic banded. *: P <0.05 vs. age-matched sham. 
#: P<0.05 vs. age-matched AB. 
 
 
Figure 19. Direct comparison of left ventricular hypertrophy regression between the early and 
the late debanded groups. Left ventricular mass (LVmass) (A), anterior wall thickness in diastole 
(AWTd) (B) and posterior wall thickness in diastole (PWTd) (C) regressed to a similar extent in 





5.2.2. Effect of early and late debanding on pathological hypertrophy markers 
In the AB groups CD, HW/TL and the expression of the fetal genes (β/α-MHC and 
ANP) were increased compared to the age-matched control groups (Fig. 20-22).  
Both in the early and in the late debanded groups, CD, HW/TL and the expression of 
the fetal genes (β/α-MHC and ANP) were decreased compared to the age-matched AB 
groups (Fig. 20A, C, Fig. 21 and Fig. 22A, C). Regarding CD (Fig. 20B), HW/TL (Fig. 
20D) and β/α-MHC (Fig. 22B), no differences could be detected in the extent of 
regression between the early- and the late debanded groups. However, the relative mRNA 
expression level of ANP decreased to a greater extent in the early debanded compared to 
the late debanded group (Fig. 22D). 
 
 
Figure 20. Effect of early and late debanding on macroscopic and microscopic myocardial 
hypertrophy markers.: Cardiomyocyte diameter (CD) and heart weigth-to-tibial length ratio 
(HW/TL) were increased in the aortic banded (AB) groups at week 12 and 18 compared to their 
age-matched sham groups. Both early and late debanding resulted in substantial decrement of CD 
and HW/TL (A, C). No differences could be observed in the extent of CD and HW/TL regression 






Figure 21. Representative microphotographs demonstrating enlargement of cardiomyocytes in 
the aortic banded (AB) groups and their regression in both the early and late debanded groups: 
Hematoxylin and eosin (magnification 200x, scale bar: 100µm) stained sections are shown. AB 
indicates aortic banding. 
 
 
Figure 22. Fetal gene expression during pressure unloading-evoked reverse remodeling. Beta-
to-alpha myosin heavy chain ratio (β/α-MHC) and atrial natriuretic peptide (ANP) were increased 
in the aortic banded (AB) groups at week 12 and 18 compared to the sham groups. Both early and 
late debanding resulted in substantial decrement of β/α-MHC and HW/TL (A, C). Although, β/α-
MHC showed similar extent of regression in the debanded groups (B), ANP normalized to a 




5.2.3. Effect of early and late debanding on reactive myocardial fibrosis 
In the early debanded group, interstitial and perivascular fibrosis decreased compared 
to the age-matched AB group (Fig. 23A, C and Fig. 24). However, in the late debanded 
group, interstitial and perivascular fibrosis remained increased, and it did not differ from 
the age-matched AB group (Fig. 23A, C and Fig. 24). Accordingly, the extent of both 
interstitial and perivascular fibrosis showed significantly higher levels in the late 
debanded group compared to the early debanded group (Fig.23B, D).  
 
 
Figure 23. Regression of interstitial and perivascular fibrosis after pressure unloading at 
different time points. Increased interstitial and perivascular fibrosis were observed in the aortic 
banded (AB) groups at week 12 and 18. Regression of reactive interstitial and perivascular fibrosis 
could be detected only in the early debanded group, while the collagen accumulation persisted in 
the late debanding group (A, C). Accordingly, robust differences were observed in interstitial and 





Figure 24. Representative histological photomicrographs of interstitial and perivascular 
fibrosis demonstrating regression of reactive fibrosis in the early debanded group and 
persisting collagen accumulation in the late debanded group. Representative photomicrographs 
of picrosirius red staining are shown demonstrating interstitial fibrosis (A, C) (magnification 50x, 
scale bar: 200µm) and perivascular fibrosis (B, D) (magnification 100x, scale bar: 100µm). AB: 
aortic banding.  
 
In the AB groups increased mRNA levels of CTGF were detected (Fig. 25A). The 
protein level of CTGF showed a strong tendency towards increased values in the AB-
wk12 group compared to the age-matched sham group. Furthermore, in the AB-wk18 
groups, the protein level of CTGF was significantly increased compared to the 




level of CTGF was normalized in both the early and the late debanding groups (Fig. 25A, 
C). No differences could be observed in the extent of CTGF regression between the two 
debanded groups (Fig. 25B, D).  
 
 
Figure 25. Effect of early and late debanding on connective tissue growth factor (CTGF) 
mRNA and protein expression. CTGF mRNA expression was increased in the aortic banded 
groups at week 12 and 18 (A). Furthermore, protein expression of CTGF was also significantly 
higher in the AB-wk18 group compared to its corresponding sham group (C). Both early and late 
debanding effectively normalized the AB-associated alterations in CTGF mRNA and protein 
expression (A, C). No differences could be observed in the extent of CTGF normalization in the 
early and late debanding groups (B, D) GAPDH: glyceraldehyde 3-phosphate dehydrogenase. *: 
P<0.05. 
 
5.2.4. Effect of early and late debanding on hemodynamic parameters 
5.2.4.1. Arterial loading and meridional wall stress 
In the AB groups SBP, DBP, MAP and σ were increased compared to the age-matched 




the AB groups at different time points (Table 7). However, σ increased to a significantly 
greater degree in the AB-wk12 and AB-wk18 groups compared to the AB-wk6 group 
(Table 7). In the early and late debanded groups, SBP, DBP, MAP and σ were decreased 
compared to the age-matched AB groups (Table 6). The extent of afterload and wall stress 
reduction did not differ between the two debanded groups (Table 7). 
 
5.2.4.2. Load-dependent systolic parameters 
In the AB-wk12 and AB-wk18 groups, EF was significantly reduced, while SV and 
CO showed a tendency towards decreased values when compared to their age-matched 
control groups (Table 6, Fig. 26A and Fig. 27). Both in the early and in the late debanded 
groups, EF, SV and CO were increased compared to the age-matched AB groups (Table 
6, Fig. 26A and Fig. 27). No differences were found regarding the extent of EF, SV and 




Figure 26. Changes in ejection fraction (EF) during the development of pathological 
myocardial hypertrophy and its regression by early and late debanding. Both the early 
debanding and the late debanding groups were associated with increased EF (A). The extent of 







Figure 27. Representative left ventricular (LV) pressure-volume (P-V) steady-state loops 
demonstrating the effect of early and late debanding on left ventricular function. In the aortic 
banded (AB) groups at week 12 and 18, the width of the loops was substantially smaller compared 
to the corresponding age-matched sham groups, suggesting impaired LV systolic function. Both 
early and late debanding effectively increased the width of the P-V loops, indicating that pressure 
unloading therapy performed either at early or late time points successfully improved LV systolic 





Table 6. Hemodynamic parameters in the aortic banded (AB) groups at different time points and in the early and the late debanded groups. Values 
are expressed as mean ± standard error of the mean. AB indicates aortic banding; SBP: systolic arterial blood pressure; DBP: diastolic arterial blood 
pressure; MAP: mean arterial pressure; σ: meridional wall stress, HR: heart rate; dP/dtmax: maximal slope of systolic pressure increment; dP/dtmin: maximal 
slope of diastolic pressure decrement; LVEDP: left ventricular (LV) end-diastolic pressure; LVESP: LV end-systolic pressure; LVEDV: LV end-diastolic 
volume; LVESV: LV end-systolic volume; SV: stroke volume; CO: cardiac output. *: P<0.05 vs. age-matched Sham, #: P<0.05 vs. age-matched AB. 













SBP, mmHg 139±4 214±5* 169±3*# 152±5 226±5* 181±4*# 
DBP, mmHg 110±3 154±5* 127±3*# 121±4 167±4* 134±2*# 
MAP, mmHg 120±4 174±4* 141±3*# 132±4 187±4* 150±3*# 
σ, kdyn/cm2 13.9±0.3 27.8±1.6* 18.3±1.1*# 18.9±0.8 37.9±2.0* 25.4±1.5*# 
HR, beats/min 356±6 365±7 357±7 381±7.5 359±4.7* 351±5.1* 
dP/dtmax, mmHg/s 8291±353 10579±436* 9467±483 9670±359 11062±505 9522±267# 
dP/dtmin, mmHg/s -9220±313 -9633±277 -9887±563 -10266±328 -8838±437* -8907±237* 
LVEDP, mmHg 4.0±0.4 7.1±0.9* 5.3±0.7 5.4±0.4 7.8±1.0* 5.8±0.4 
LVESP, mmHg 133±3 202±4* 161±4*# 147±5 209±5* 168±5*# 
LVEDV, µl 340±19 357±18 340±16 329±19 372±19 362±13 
LVESV, µl 148±13 201±11* 166±10 150±10 216±12* 166±13# 
SV, µl 192±10 156±12 174±10 178±11 156±17 196±14 





Table 7. Comparison of pressure overload-induced alterations in the aortic banded groups at different time points and during myocardial reverse 
remodeling after early and late debanding. The values of the aortic banded (AB) and the debanded groups were normalized to the corresponding sham 
groups. These calculated values are expressed as mean ± standard error of the mean. SBP indicates systolic arterial blood pressure; DBP: diastolic arterial 
blood pressure; MAP: mean arterial pressure; Ea: arterial elastance, σ: meridional wall stress, LVEDP: left ventricular end-diastolic pressure; LVESP: 
LV end-systolic pressure; LVEDV: LV end-diastolic volume; LVESV: LV end-systolic volume; SV: stroke volume; CO: cardiac output. *: P<0.05 vs. 
age-matched Sham.  













(early verus late 
debanded) 
ΔSBP, % 50±3 55±4 49±3 21±2 19±3 0.53 
ΔDBP, % 32±2 39±4 38±3 14±3 11±2 0.38 
ΔMAP, % 39±2 45±4 42±3 17±3 14±2 0.40 
Δσ, % 33±11 100±12* 101±11* 31±8 36±8 0.65 
ΔLVEDP, % 51±21 79±23 46±19 31±16 9±7 0.21 
ΔLVESP, % 52±4 53±3 43±3 22±3 15±3 0.10 
ΔLVEDV, % 7±6 5±5 13±6 1±5 10±4 0.13 
ΔLVESV, % 23±8 35±7 44±8 11±7 11±8 0.98 
ΔSV, % -5±6 -19±6 -13±9 -8±5 10±8 0.07 





5.2.5.3. Load-independent contractility parameters  
In the AB-wk12 and AB-wk18 groups, neither ESPVR nor PRSW differed from their 
corresponding control groups (Fig. 28, 29A, 30A). Similarly, no alteration could be 
observed in ESPVR and PRSW after early or late debanding. (Fig. 28, 29A, 30A).  
 
 
Figure 28. Representative pressure volume loops demonstrating characteristic alterations in 
the aortic banded (AB) groups and in the early and late debanded groups. Original recordings 
were obtained at different preloads during transient vena cava occlusion. The slope of end-systolic 
pressure volume relationship (ESPVR) did not differ among the study groups. In contrast, the 
slope of the end-diastolic pressure volume relationship (EDPVR) was increased in the AB groups, 
suggesting impaired myocardial stiffness. Increased EDPVR was normalized in the early 






Figure 29. Alterations in preload recruitable stroke work (PRSW) after early and late 
debanding. PRSW did not differ in the aortic banded (AB) groups at week 12 and week 18 from 
the corresponding control groups (A). Similarly, no alterations could be detected in PRSW neither 
in the early nor in the late debanding groups (A, B). *: P<0.05. 
 
5.2.5.4. Ventriculo-arterial coupling 
In the AB-wk12 and AB-wk18 groups, ESPVR did not differ from the control groups 
(Fig. 30A). Therefore, at these time points, increased Ea (Fig. 30C) was not compensated 
by enhanced contractility, which led to impaired VAC (Fig. 30E). Both in the early- and 
in the late debanded groups, reduction of Ea efficiently normalized the relation of the LV 
contractility and the connecting arterial system and resulted in adequate VAC values (Fig. 
30E). No differences could be observed in the extent of VAC normalization between the 





Figure 30. Ventriculo-arterial coupling (VAC) during the development of aortic banding (AB)-
induced pathological myocardial hypertrophy and during its regression by early and late 
debanding. The slope of end-systolic pressure-volume relationship (ESPVR) did not differ among 
the study groups (A-B). In contrast arterial elastance (Ea) was significantly increased in the aortic 
banded (AB) groups at week 12 and 18 (C). Both early and late debanding effectively reduced 
the increased Ea (C). The extent of Ea normalization was similar between the two debanded 
groups (D). The lack of compensatory contractility augmentation led to impaired ventriculo-
arterial coupling (VAC) in the AB groups at week 12 and 18. By decreasing Ea, both early and 
late debanding resulted in the normalization of VAC. No differences could be detected in the 
improvement of VAC between the early and the late debanded groups. *: P<0.05. 
 
5.2.5.5. Diastolic parameters 
Tau was prolonged in all the AB groups (Fig. 31A). Furthermore, the slope of EDPVR 
was also increased in AB groups at week 12 and 18 compared to sham (Fig. 31C). In the 




did not differ from the control’s level (Fig. 31A). In the late debanded group, Tau was 
also decreased compared to the age-matched AB group. However, the extent of 
improvement was smaller compared to the early debanded group and Tau remained 
significantly prolonged in the late debanded group when compared the control’s level 
(Fig. 31A-B). Furthermore, in the early debanded group, LV stiffness was also decreased 
compared to the corresponding AB group (Fig. 31C). In contrast, no significant 
differences could be observed in EDPVR between the late debanded group and the AB-
wk18 group (Fig. 31C). Therefore, the extent of improvement in LV stiffness was also 
significantly smaller in the late debanded group than that observed in the early debanded 
group (Fig. 31D). 
 
 
Figure 31. Diastolic function during the development of aortic banding (AB)-induced LVH 
and its regression by early and late debanding. Prolongation of the active relaxation time 
constant (Tau) and increased myocardial stiffness (assessed by the elevated slope of the end-
diastolic pressure-volume relationship [EDPVR]) were detected in the AB groups at week 12 and 
18 (A, C). Debanding the aortic constriction at an early time point effectively improved both 
aspects of diastolic function (A, C). In contrast, late debanding failed to normalize diastolic 
dysfunction. Accordingly, robust differences were observed between the early and the late 




5.3. Investigation of sex differences during the development of pressure overload-
induced left ventricular hypertrophy 
5.3.1. Effect of sex on the temporal development of left ventricular hypertrophy 
LV mass index was increased in both male and female AB rats from week 3 until the 
end of the experimental period (Fig. 32 and Fig. 33A). RWT revealed concentric LV 
geometry at week 6 in both male and female AB groups (Fig 32 and Fig. 33C). 
Concentric geometry was also observed in the female AB rats at week 12. However, at 
week 12, RWT substantially decreased in male rats, leading to eccentric LV geometry 
(Fig. 33C). Furthermore, reduction of EF was only observed in the male AB-wk12 group 
(Fig. 33A).  
 
Figure 32. Representative echocardiographic recordings demonstrating sex-related differences 
in male and female aortic banded (AB) rats at week 12. The female AB was associated with 
increased left ventricular (LV) wall thicknesses, concentric geometry and maintained systolic 
function. In contrast the male AB was characterized by increased LV wall thicknesses, eccentric 
remodeling and decreased systolic function. AWT indicates anterior wall thickness, PWT: 
posterior wall thickness, LVEDD: left ventricular end-diastolic diameter, LVESD: left ventricular 







Figure 33. Echocardiographic follow-up during the development of pressure overload-induced 
myocardial hypertrophy in male and female rats. The female aortic banded (AB) group was 
associated with maintained ejection fraction (A), enhanced left ventricular (LV) mass index (B) 
and increased relative wall thickness (C) at both early (week 6) and later time points (week 12). 
The male AB group was also characterized by preserved ejection fraction (A), increased LV mass 
index (B) and increased relative wall thickness (C) at a relatively early time point (week 6). 
However, deterioration of ejection fraction (A) and decrement of relative wall thickness (B) took 
place in male AB rats at week 12, leading to substantial differences between the two sexes. *P < 
0.05 vs. age and sex-matched sham. #: P<0.05 vs. female AB. 
 
5.3.2. Sex differences in pathological hypertrophy and fibrosis markers 
Week 6. At this early stage, HW/TL, CD, myocardial collagen area and CTGF mRNA 
levels were enhanced in both male and female AB rats compared to their age- and sex-
matched sham groups (Fig. 34-37). The extent of hypertrophy and fibrosis was 
comparable between the two sexes at this early time point (Table 8).  
Week 12. At this later stage, the hypertrophy and fibrosis markers were also increased 
in male and female AB rats compared to their sham groups (Fig. 34-37). However, the 
direct comparison of sexes revealed higher increments in HW/TL and CD in females 
compared to males (Table 8). In contrast, fibrosis showed significant progression from 
week 6 to week 12 only in male AB rats (Fig. 35 and Fig. 37). Furthermore, the extent 
of AB-associated increment in CTGF expression was also significantly higher in males 






Figure 34. The effect of sex on myocardial hypertrophy markers. Heart weight-to-tibial length 
(HW/TL) and cardiomyocyte diameter (CD) were increased in male and female aortic banded 






Figure 35. The effect of sex on fibrosis markers. Collagen area and mRNA level of connective 
tissue growth factor (CTGF) were increased in male and female aortic banded (AB) rats at week 
6 and 12 as well when compared to their age-matched sham groups. Furthermore, fibrosis showed 
significant progression from week 6 to week 12 in male AB rats, while in female AB rats the 





Table 8. Comparison of pressure overload-induced morphological, ultrastructural and 
molecular alterations in the aortic banded groups in male and female rats at different time 
points. The values of the aortic banded groups were normalized to the corresponding sham 
groups. These calculated values are expressed as mean ± standard error of the mean. LV indicates 
left ventricle; RWT: relative wall thickness; HW/TL: heart weight-to-tibial length; CD: 
cardiomyocyte diameter; CTGF: connective tissue growth factor. 
















ΔLV mass index, 
% 
49±5 47±12 0.90 46±4 47±8 0.88 
ΔRWT, % 27±4 29±11 0.84 13±5 28±11 0.21 
ΔHW/TL, % 34±4 47±8 0.13 31±2 46±8 <0.05 
ΔCD, % 28±4 30±9 0.78 17±4 31±5 0.04 
ΔFibrosis area, % 70±15 59±15 0.60 108±20 69±17 0.19 
ΔCTGF, % 193±50 272±39 0.24 557±99 162±36 <0.01 
 
 
Figure 36. Representative photomicrographs demonstrating enlargement of cardiomyocytes in 
the aortic banded (AB) male and female groups at week 6 and 12. Hematoxylin and eosin 







Figure 37. Representative histological photomicrographs demonstrating enhanced interstitial 
fibrosis in male and female aortic banded (AB) rats. Picrosirius red-stained sections 
(magnification 50x, scale bar: 200 µm) are shown. Collagen accumulation (indicated by the red 
area) was observed in both male and female AB rats at week 6. Furthermore, fibrosis was 
progressed to a greater extent in male but not in female AB rats at week 12.  
 
5.3.2. Characteristic sex-related functional differences  
 
5.3.2.1. Arterial loading  
At week 6 and 12, in both male and female AB rats increased SBP, DBP and MAP 
confirmed the presence of increased afterload (Table 9).  
 
5.3.2.2. Load-dependent systolic parameters 
Week 6. After 6 weeks of sustained PO, the AB groups were associated with preserved 
EF in both genders (Fig. 38 and Table 9.) Furthermore, in female AB rats, SV and CO 
were slightly increased compared to the corresponding control group (Table 9).  
Week 12. At week 12, reduced EF was confirmed in the male AB group (Fig. 38 and 
Table 9). In contrast, the values of EF did not differ from the corresponding sham group 
in female AB animals. The different alterations in EF resulted in significant difference 
between the two genders (Table 10). Furthermore, the parameters of SV and CO showed 
also a tendency towards decreased values in the male AB group, while these tendencies 





Figure 38. Representative steady-state pressure-volume (P-V) loops in male and female aortic 
banded and sham rats at different time points. photomicrographs demonstrating enhanced 
interstitial fibrosis in male and female aortic banded (AB) rats. The width of the P-V loops in 
the male and female AB groups at week 6 was similar to the controls’, indicating preserved 
systolic function. In contrast, the width of the P-V loops was smaller in the male AB group 
compared to the male sham group at week 12, suggesting deterioration of systolic performance. 
In contrast to males, the width of the P-V loops in females remained at the control’s level at week 






Table 9. Hemodynamic parameters in male and female rats 6 and 12 weeks after aortic banding or sham operation. Values are expressed 
as mean ± standard error of the mean. AB indicates aortic banding; SBP: systolic arterial blood pressure; DBP: diastolic arterial blood pressure; MAP: 
mean arterial pressure; HR: heart rate; dP/dtmax: maximal slope of systolic pressure increment; dP/dtmin: maximal slope of diastolic pressure decrement; 
LVESP: left ventricular end-systolic pressure; LVEDP: LV end-diastolic pressure; LVEDV: LV end-diastolic volume; LVESV: LV end-systolic volume; 
SV: stroke volume; EF: ejection fraction; CO: cardiac output; Tau: time constant of LV pressure decay according to the Glantz’ method; EDPVR: end-
diastolic pressure-volume relationship. *: P<0.05 vs. age-matched Sham. #: P<0.05 vs. AB-wk6.  
 Male Female 
 6 week 12 week 6 week 12 week 
 Sham AB Sham AB Sham AB Sham AB 
SBP, mmHg 144±6 216±5* 137±5 211±4* 144±3 232±10* 140±5 224±12* 
DBP, mmHg 112±5 150±3* 110±4 152±5* 112±2 167±6* 110±5 156±7* 
MAP, mmHg 123±5 172±3* 119±4 172±4* 123±2 188±7* 120±5 179±8* 
HR, beats/min 355±7 361±9 360±4 362±8 362±9 372±10 374±15 381±7 
dP/dtmax, mmHg/s 7960±310 11080±390* 8230±350 10670±410* 8820±410 12040±890* 9500±350 13240±560* 
dP/dtmin, mmHg/s -8640±240 -11120±350* -9590±280 -9630±290# -10640±590 -12580±650 -10720±420 -13190±1060 
LVEDP, mmHg 4.0±0.7 5.7±0.6 3.7±0.4 6.4±0.9* 3.7±0.2 4.8±0.7 3.2±0.4 3.3±0.5 
LVESP, mmHg 132±3 201±6* 126±4 196±3* 139±4 202±10* 140±3 210±9* 
LVEDV, µl 307±17 364±5 346±21 373±21 263±25 320±14 295±5 297±9 
LVESV, µl 132±13 175±9 150±13 207±13* 127±15 136±15 136±5 146±6 
SV, µl 175±18 189±9 196±12 166±13 136±11 184±8* 159±8 151±11 
EF, % 57±4 52±2 57±2 44±2* 54±3 58±3 54±2 51±3 
CO, ml/min 63.0±7.1 68.0±3.2 70.8±4.7 59.8±4.7 48.5±3.0 68.4±4.1* 59.1±3.2 57.7±4.7 
Tau, ms 13.8±0.4 17.9±0.6* 12.3±0.6 19.4±0.8* 12.3±0.6 15.5±1.0* 12.0±0.4 15.9±1.3* 




5.3.2.3. Load-independent contractility parameters 
Week 6. At this early-stage, the load-independent indices of cardiac contractility 
(PRSW and ESPVR) were significantly increased in both male and female AB groups 
when compared to their control groups (Fig. 39, Fig. 40A and Fig. 41A). The direct 
comparison of the two sexes revealed no significant differences in the extent of 
contractility augmentation at this time point (Fig. 40B, Fig. 41B).  
Week 12. At this later stage, a significant reduction from the 6-week state could be 
observed in PRSW and ESPVR among male AB rats. In contrast, in female animals, LV 
contractility remained increased, and PRSW and ESPVR were significantly higher when 
compared to the corresponding sham group (Fig. 39, Fig. 40A and Fig. 41A). The 
differences in contractility changes between male and female rats were well reflected by 
direct gender comparison, which showed significantly greater increments in PRSW and 
ESPVR in females (Fig. 40B and Fig. 41B).  
 
Figure 39. Representative Pressure-Volume loops demonstrating sex differences in LVH. 
Original recordings were obtained at different preloads during transient vena cava occlusion and 
show steeper slope of the end-systolic P-V relationship (ESPVR) in male and female aortic 
banded (AB) rats at week 6, suggesting enhanced contractility. At week 12, in the AB groups, the 






Figure 40. Alterations in preload recruitable stroke work (PRSW) in male and female aortic 
banded (AB) rats. PRSW was enhanced in both male and female AB rats at week 6 (A) compared 
to their corresponding sham groups. Female AB rats demonstrated increased PRSW at week 12 
as well. In contrast, the augmented LV contractility (increased PRSW) reduced to the control’s 
level in male AB rats at week 12 (A). Accordingly, robust differences were observed in PRSW 
between the two sexes at week 12 (B). *: P<0.05. 
 
5.3.2.4. Ventricular-arterial coupling 
Week 6. At this early stage, augmentation in ESPVR exceeded the increment in Ea, 
resulting in preserved VAC ratio in the AB groups in both genders. Furthermore, the 
robust increment of ESPVR in female animals resulted in functional overcompensation, 
as reflected by reduced VAC ratio (Fig. 41E).  
Week 12. At this later stage, reduction of contractility in male AB rats led to an 
impairment in the VAC ratio, which showed significantly higher values in AB week 12 
group when compared to AB week 6 group.  On the contrary, the maintained contractility 
augmentation in female AB rats ensured preserved VAC ratio even after 12 weeks of PO. 






Figure 41. Sex differences in ventriculo-arterial coupling (VAC) during the development and 
progression of pressure overload-induced myocardial hypertrophy. The contractility 
augmentation (assessed by increased slope of end-systolic pressure-volume relationship [A]) 
counterbalanced the increased arterial elastance (Ea) (C), leading to maintained ventriculo-arterial 
coupling (E) in both male and female AB rats at week 6 and in female AB rats at week 12. In 
contrast, the contractility augmentation was diminished in the male AB group at week 12 (A, B) 
leading to impaired VAC ratio (E, F).  *: P<0.05 
 
5.3.2.5. Diastolic parameters 
Week 6. The AB groups were associated with prolonged Tau in both sexes when 
compared to the corresponding sham groups, indicating impaired relaxation. The degree 




Week 12. At this stage, prolongation of Tau was also evident in both male and female 
AB rats. However, at this time, impairment of active relaxation occurred at a significantly 
greater extent in male AB rats when compared to that of female littermates (Table 9-10). 
Increment of LV mass index showed strong correlation with prolongation of Tau (r=0.53; 
p<0.01). Furthermore, LVEDP and the slope EDPVR were also consistently elevated in 
male but not in the female AB animals at week 12, leading to substantial differences 
between the two genders (Table 9-10). In addition, a significant correlation was detected 
between LVEDP and collagen area (r=0.30; p=0.02) and also between EDPVR and 
collagen area (r=0.28; p=0.03). 
 
Table 10. Comparison of pressure overload-induced functional alterations between the two 
sexes The values of the aortic banded groups were normalized to the corresponding sham groups. 
Values are expressed as mean ± standard error of the mean. SBP: systolic arterial blood pressure; 
DBP: diastolic arterial blood pressure; MAP: mean arterial pressure; HR: heart rate; dP/dtmax: 
maximal slope of systolic pressure increment; dP/dtmin: maximal slope of diastolic pressure 
decrement; LVEDP: LV end-diastolic pressure; LVESP: LV end-systolic pressure; LVEDV: LV 
end-diastolic volume; LVESV: LV end-systolic volume; SV: stroke volume; EF: ejection 
fraction; CO: cardiac output; Tau: time constant of LV pressure decay according to the Glantz’ 
method; EDPVR: end-diastolic pressure-volume relationship. 
















ΔSBP, % 50±3 62±7 0.14 54±3 60±8 0.99 
ΔDBP, % 34±3 49±5 0.02 38±5 42±6 0.65 
ΔMAP, % 40±3 54±5 0.03 44±4 49±7 0.54 
ΔHR, % 2±3 3±3 0.72 1±2 2±2 0.62 
ΔdP/dtmax, % 39±5 36±10 0.80 30±5 39±6 0.22 
ΔdP/dtmin, % 29±4 18±6 0.17 1±3 23±10 0.02 
ΔLVEDP, % 44±16 31±19 0.61 73±23 5±17 <0.05 
ΔLVESP, % 53±5 46±7 0.41 56±2 50±6 0.34 
ΔLVEDV, % 19±2 22±5 0.59 8±6 1±3 0.38 
ΔLVESV, % 33±7 7±12 0.07 38±8 8±4 0.01 
ΔSV, % 8±5 35±6 <0.01 -15±7 -5±7 0.32 
ΔEF, % -9±4 7±6 0.04 -22±4 -6±5 0.02 
ΔCO, % 8±5 42±8 <0.01 -16±7 -2±8 0.22 
ΔTau, % 29±4 26±8 0.69 58±6 33±11 <0.05 






The purpose of the present investigation was threefold. The first goal was to provide a 
detailed hemodynamic characterization of in vivo LV function at different stages of PO-
induced LVH. The second goal was to examine the reversibility of the PO-evoked 
structural and functional abnormalities from early and late stage LVH. Finally, the third 
goal was to examine potential sex-related differences in LV structure and function during 
the adaptation to chronic PO. 
 
6.1. Longitudinal assessment of pressure overload-induced structural and 
functional alterations of the left ventricle 
In the current study, the abdominal AB rat model was utilized to induce sustained PO 
of the LV. Based on prior literature data (61), and on our own experiences with this 
particular model (47, 57, 124), the time points of week 6, 12 and 18 were chosen to detect 
characteristic alterations of early and late stages of PO-induced LVH, respectively.  
 
6.1.1. Structural and molecular alterations during the development and 
progression of pressure overload-induced left ventricular hypertrophy 
The two main ultrastructural characteristics of PO-induced LVH are cardiomyocyte 
hypertrophy and myocardial fibrosis (134). Previous research work has provided clear 
evidence that the development of cardiomyocyte hypertrophy precedes the manifestation 
of myocardial fibrosis during PO-evoked pathological remodeling. Hence at a relative 
early stage, cardiomyocyte hypertrophy and low level of myocardial fibrosis are the 
dominant histopathological findings, whereas at later stages cardiomyocyte hypertrophy 
is accompanied by progressive collagen accumulation (16). 
In the current study, development of marked myocardial hypertrophy was observed in 
the AB group at week 6, as indicated by echocardiographic data (increased wall 
thicknesses and LVmassindex), post mortem measurement (increased HW/TL) and 
histological analysis (increased cardiomyocyte width). The pathological nature of 
myocardial hypertrophy was confirmed by the reactivation of the fetal gene program 




robust myocardial hypertrophy, interstitial fibrosis remained at a relatively low level in 
the AB group at week 6. 
The macroscopic, microscopic and molecular hypertrophy markers were also 
markedly elevated in the AB groups at week 12 and 18. In addition, at these later time 
points, AB was also associated with chamber dilatation (increased LVEDD) and 
progressive accumulation of the interstitial collagen content).  
 
6.1.2. Characterization of left ventricular systolic function and contractility 
during the development and progression of pathological hypertrophy  
Traditionally, the echocardiography-derived load-dependent indices have been 
utilized to describe alterations in LV systolic function during the development of PO-
induced LVH and its transition to HF (135). Calculation of these parameters have 
indicated that systolic function is preserved at a relatively early stage of LVH. However, 
as PO-induced LVH advances, systolic function becomes progressively impaired. 
Nevertheless, it is important to note that the robust alterations in afterload makes the 
conventional load-dependent parameters inappropriate for the characterization of intrinsic 
LV function under sustained PO (e.g. AS, AH or abdominal AB). In contrast, the 
assessment of P-V loops at different preloads enables the calculation of in vivo LV 
contractility parameters independently of loading conditions. Hence, in the current study 
we performed P-V analysis to gain a deeper understanding of the dynamic alterations of 
LV contractility at different stages of PO-induced LVH.  
To assess LV contractility, three load-independent gold standard parameters (ESPVR, 
PRSW and dP/dtmax-EDV) were calculated from P-V analysis data (136). All of these 
sensitive indices were substantially increased in the AB-wk6 group, confirming enhanced 
LV contractility at a relatively early stage of PO-evoked LVH. Of particular interest, 
calculation of VAC (the ratio of arterial afterload to LV contractility) has revealed that 
the augmentation of LV contractility efficiently counterbalanced the increment in arterial 
afterload (Ea) in the AB group at week 6. Consistent with this finding, the load-dependent 
parameters of LV systolic function (e.g. EF) were maintained at this early stage of PO-
induced LVH.  
In contrast, at more advanced stages of PO-induced LVH (in the AB-wk12 and AB-




PRSW and dP/dtmax-EDV in the AB-wk6 group) diminished. The decompensation of the 
hypercontractile state combined with the persistently increased arterial afterload (Ea) 
resulted in a contractility-afterload mismatch (impaired VAC ratio). Therefore, at these 
later time points the net systolic performance became decreased, which was reflected by 
the reduction of load-dependent systolic parameters (e.g. EF).  
Although LV systolic function decreased in the AB-wk12 and AB-wk18 groups, it is 
important to point it out that LV contractility did not differ from the corresponding sham 
groups. These hemodynamic results are of particular importance, providing evidence that 
increased arterial afterload and not impaired LV contractility is predominantly 
responsible for the systolic dysfunction in the abdominal AB rat model. Our findings are 
in good agreement with the reports of R. J. Hajjar, demonstrating severely reduced 
systolic function but normal LV contractility in the TAC model (60). 
 
6.1.3. Characterization of LV diastolic function during the development and 
progression of pathological hypertrophy 
Impairment of diastolic function is a hallmark of PO-induced pathological LVH. 
Importantly, both components of diastole, namely active relaxation and passive filling 
have been reported to deteriorate under sustained PO. 
Active relaxation. Of particular interest is the observation that prolongation of active 
relaxation occurs early after PO induction. Consistent with this statement, numerous 
investigations have documented impaired ventricular relaxation already at early stages of 
PO-induced LVH (47, 66). In line with the data of previous research, we observed 
increased values of Tau in the AB group already at week 6. Prolongation of active 
relaxation was also evident in the AB-wk12 and AB-wk18 groups.  
Passive filling. Passive filling is predominantly determined by the structural 
composition of the LV walls. One of the main pathogenic alterations that underlies the 
reduced LV compliance in PO-induced LVH is increased myocardial fibrosis (137). In 
the current investigation, neither the amount of interstitial fibrosis nor the slope of 
EDPVR (the P-V derived parameter of ventricular stiffness) differed in the AB-wk6 
group from the control’s value. In contrast, at later stages the robust increase in interstitial 





6.2. Investigating the effects of myocardial reverse remodeling from early- versus 
late-stage left ventricular hypertrophy  
As described above, we have established two distinct stages of PO-induced LVH by 
utilizing the abdominal AB rat model for different time periods. The structural and 
functional alterations of the LV in the AB group at week 6 met the criteria of an early 
stage of PO-induced LVH. Accordingly, marked myocardial hypertrophy, relatively low 
levels of myocardial fibrosis, preserved systolic function and impaired active relaxation 
were observed in the AB-wk6 group. In contrast, at more advanced stages (at week 12 
and week 18) typical signs of late-stage LVH were detected. In accordance, robust 
myocardial hypertrophy, severe myocardial fibrosis, impaired systolic function, 
prolonged active relaxation and increased myocardial stiffness were noted in the AB-
wk12 and AB-wk18 groups.  
Current guidelines recommend AVR/TAVI for AS patients at advanced stages, when 
HF symptoms are already present and/or LV systolic function is reduced (138). However, 
it has been increasingly recognized that HF symptoms and LV dysfunction often persist 
even after successful pressure unloading therapies (71). Hence, it has been suggested that 
performing surgeries at earlier time points might provide a greater improvement in LV 
function and HF symptoms compared to the current late-stage interventions. Based on 
this, in the next set of experiments our goal was to investigate whether removing the aortic 
constriction at an earlier time point could induce a reverse remodeling process to a greater 
extent in regard to structural, molecular and functional alterations compared to a late-
stage intervention. To address these questions, the aortic constriction was removed in two 
subgroups of AB animals at week 6 (early debanding) or week 12 (late debanding). The 
reverse remodeling processes were then examined after a subsequent 6 week-long follow-
up periods.  
 
6.2.1. Regression of myocardial hypertrophy after early and late debanding 
Ample evidence has accumulated supporting the notion that myocardial hypertrophy 
effectively regresses after pressure unloading therapy (70, 72). In concordance with 
earlier findings, the present study also found that removal of the aortic constriction led to 
substantial regression of myocardial hypertrophy from both early- and late-stage LVH. 




and the late debanded groups either on macroscopic (LV mass, AWTd, PWTd, HW/TL), 
microscopic (CD) or gene expression level (β/α MHC ratio). Furthermore, the regression 
of myocardial hypertrophy also displayed a similar time course in the early and the late 
debanded groups. Accordingly, in both experimental groups, regression of myocardial 
mass almost reached its full extent after 3 weeks of pressure unloading. The comparable 
degree of hypertrophy regression in the early and late debanded groups could be explained 
by the fact that the same degree of afterload (ΔSBP, ΔDBP, ΔMAP, ΔEa) and meridional 
wall stress (Δσ) reduction was achieved in both cases.  
 
6.2.2. Regression of reactive myocardial fibrosis after early and late debanding 
Both clinical and preclinical data exist demonstrating that reactive myocardial fibrosis 
regresses in a significantly slower fashion after pressure unloading therapy compared to 
myocardial hypertrophy (72, 88). Accordingly, the first histopathological evidence for 
the resorption of interstitial collagen fibers is often observed only years after AVR (64, 
65, 72, 74). In the current study, removing the aortic constriction at week 6 (when LVH 
was associated with relatively low level of interstitial fibrosis) efficiently attenuated the 
accumulation of reactive myocardial fibrosis (both interstitial and perivascular) in the 
myocardium during the 6-week-long observation period. These results are in agreement 
with our previous findings using this model (124, 139). On the contrary, removal of the 
aortic constriction at week 12 (when LVH was associated with severe reactive myocardial 
fibrosis) did not lead to a regression of reactive interstitial and perivascular fibrosis during 
the 6-week-long follow-up. In line with our findings, in a previous pre-clinical study with 
a similar experimental approach (comparing early and late debanding), normalization of 
perivascular collagen content also occurred to a greater extent in the early debanded group 
compared to the late debanded group (91).  
Surprisingly, CTFG, which is one of the master regulators of cardiac fibrosis, showed 
decreased mRNA and protein expression in the late debanded group as well. This is of 
particular interest, as it has been previously demonstrated that inhibition of CTGF 
expression can induce the regression of pre-established tissue fibrosis (140). Thus, the 
observed robust decrease in the expression of CTGF may indicate that regression of 
reactive fibrosis would have also occurred in the late debanded group in case of a longer 





6.2.3. Effect of complete versus incomplete structural reverse remodeling on left 
ventricular systolic and diastolic function 
We would like to call the reader’s attention to the fact that in the early debanded group 
both myocardial hypertrophy and fibrosis regressed. In contrast, in the late debanding 
group, only myocardial hypertrophy was normalized while myocardial fibrosis persisted 
six weeks after the removal of the aortic constriction. Therefore, our experimental 
approach allowed us to investigate the effect of complete versus incomplete structural 
reverse remodeling on different aspects of LV function under laboratory conditions. 
 
6.2.3.1. Recovery of left ventricular systolic function after early and late 
debanding 
Removal of chronic PO often induces a rapid improvement in systolic function, even 
before the normalization of LV structural abnormalities (especially fibrosis) is completed 
(70, 96). This phenomenon can be underpinned by the fact that at certain stages of PO-
induced LVH, the increased arterial loading condition (due to AS, AH or AB) and not the 
depressed LV contractility is primarily responsible for the contractility-afterload 
mismatch and thus for the reduced systolic function (141). As such, it can be hypothesized 
that in these cases the acute relief of afterload can lead to sudden normalization of VAC 
and thereby increment in ejection performance. As mentioned above, at the early stage of 
LVH (AB-wk6 group) LV contractility was enhanced, VAC was maintained and EF was 
preserved. In contrast, at later stages of LVH (week 12 and week 18) the compensatory 
augmentation of LV contractility was diminished. Therefore, in the AB-wk12 and AB-
wk18 groups impaired VAC and reduced EF were detected. However, it is important to 
highlight that even in the late stage groups the increased arterial afterload (Ea) and not 
the depressed LV contractility was the source of the observed contractility-afterload 
mismatch. In correspondence, reduction of Ea after pressure unloading successfully 
normalized the VAC ratio in the late debanded group similarly to the early debanded 





6.2.3.2. Recovery of left ventricular diastolic function after early and late 
debanding 
In contrast to systolic function, diastolic dysfunction has been reported to persist for 
years after the termination of the pathological stimulus of PO (71). This phenomenon has 
been explained by the fact that recovery of diastolic function might require a complete 
normalization of the pathological structural alterations (especially fibrosis) of the LV.  
Active relaxation. Previous research data indicates that active relaxation is extremely 
sensitive to the alterations in afterload. This is underpinned by the fact that an acute 
increase in systolic peak pressure has been found to be sufficient for the prolongation of 
active relaxation, independently from the development of LVH (142). Furthermore, 
Ikonodimis et al. showed that patients undergoing AVR experienced a significant 
improvement in myocardial relaxation early after surgery, at a time point when regression 
of LV wall thicknesses had not yet occurred (79). In accordance, we also found that 
termination of sustained PO effectively decreased the prolonged Tau in both the early and 
late debanded groups. However, the extent of Tau improvement proved to be inferior in 
the late debanded group compared to the early debanded group. This can partly be 
explained by a higher persistent stretch on the single cardiomyocytes in the late debanded 
group, which was reflected by increased ANP expression in our investigation (143). The 
enhanced tension at the myofibrillar level might have originated from ultrastructural 
differences between the early- and the late debanded groups, since at the ventricular level, 
meridional wall stress was reduced to the same degree after early and late debanding. In 
accordance with our findings, prior investigations identified persistent interstitial fibrosis 
and incomplete normalization of cardiomyocyte enlargement as potential sources of 
increased myofibrillar tension following AVR (72). In our study CD decreased to the 
same extent in the early- and the late debanded groups. Therefore, it can be inferred that 
the persistently elevated interstitial fibrosis was mainly responsible for the increased 
tension on the single cardiomyocyte level and thereby for the incomplete normalization 
of impaired active relaxation in the late debanded group. Furthermore, it has been 
suggested that severe perivascular fibrosis can reduce the oxygen supply of the 
cardiomyocytes (40), thereby decreasing the energy production of the myocardium. 
Considering the fact that active relaxation is an ATP-dependent process, an indirect 




ventricular relaxation in the hypertrophied LV. Correspondingly, the persistent 
perivascular fibrosis could have also contributed to the ineffective normalization of 
prolonged active relaxation in the late debanded group.  
Passive filling. Passive filling, representing the second component of diastole, is 
predominantly determined by the structural properties of the LV. As previously 
mentioned, enhanced interstitial collagen accumulation is one of the most important 
ultrastructural alterations that increase the stiffness of the LV. Therefore, it is not 
surprising that previous investigations have observed improvements in myocardial 
compliance only years after AVR, when regression of interstitial fibrosis had already 
taken place (64, 65). In our study, P-V derived EDPVR values also followed the 
alterations in interstitial fibrosis after pressure unloading. Accordingly, in the early 
debanded group, the relatively low level of myocardial fibrosis was associated with 
normalized EDPVR values. However, the debanding surgery at the later time point failed 
to reduce the extent of interstitial fibrosis and in parallel could not improve the increased 
passive stiffness during the 6-week long follow-up period. Therefore, our hemodynamic 
data were in accordance with previous clinical findings, demonstrating that regression of 
interstitial fibrosis is inevitable for the normalization of the increased myocardial 
stiffness. 
 
6.3. Sex differences during the development of pressure overload-induced left 
ventricular hypertrophy 
Sex differences have been suggested to play an important role in the development of 
PO-induced LVH. Accordingly, in women with long-lasting AH or AS as well as in 
female rodents with AB, smaller LV dimensions (105, 106, 109), more concentric LV 
geometry (105-107), better systolic function (105-109), less interstitial fibrosis (109, 
115), less apoptosis (101) and different regulation of genes encoding mitochondrial 
factors (118) were documented compared to their male counterparts with comparable 
mechanical overload.  
Despite the above mentioned extensive clinical and experimental research, potential 
sex-related differences with regards to LV hemodynamics have not yet been investigated. 
Hence, in the current experiment we aimed to perform P-V analysis in male and female 





6.3.1. Sex differences in myocardial hypertrophy and fibrosis 
Based on the findings of relevant animal models, sex differences in LVH may be 
attributed to the fact that following a common initial stage, progressive maladaptive 
remodeling occurs in male but not in female rodents (104). In accordance with prior 
research, we found that the early-stage of PO-induced LVH was associated with a 
comparable degree of myocardial hypertrophy, equal amounts of interstitial fibrosis and 
concentric LV geometry in both male and female AB rats. In contrast at week 12, late-
stage features of LVH were identified in male but not in female AB rats. Accordingly, at 
week 12 the male AB group was characterized by intensified fibrotic remodeling 
(indicated by increased collagen area and CTGF mRNA expression compared to the 6-
week state) and LV dilatation (leading to eccentric LV geometry. These findings stand in 
parallel with our previous experiences with the abdominal AB model (Study 1 and 2). On 
the other hand, the hypertrophied hearts in the female group still showed concentric 
geometry and a similar extent of interstitial fibrosis as observed at week 6. Furthermore, 
at this later time point, the relative extent of hypertrophy was greater in female versus 
male AB rats. These structural differences between male and female rodents at an 
advanced stage of PO-induced LVH are in line with the results of Douglas et al., who 
investigated gender-related myocardial differences in rats with 20 weeks of AB (104). 
 
6.3.2. Sex differences in left ventricular systolic function under pressure overload 
Load-dependent systolic parameters have been reported to be more preserved in female 
patients with chronic AS and female animals with experimentally induced LV PO 
compared to their male counterparts (105-107). However, potential sex-related 
discrepancies in load-independent LV contractility parameters during the development of 
PO-induced LVH have not been examined yet. As such, the present study represents the 
first attempt to characterize LV systolic function in male and female AB rats 
independently from the confounding effects of loading conditions. 
Assessment of P-V loops has revealed that both male and female AB groups were 
associated with augmented LV contractility (ESPVR, PRSW) at week 6. Calculation of 
VAC confirmed that the increment in LV contractility (ESPVR) was sufficient to 




Furthermore, in female AB animals, the excessive functional adaptation to sustained PO 
led to increased systolic performance (reflected by higher SV, CO and decreased VAC) 
at this early stage of LVH. Therefore, although systolic function was maintained in both 
male and female AB rats, the lack of functional overcompensation in males resulted in 
sex-related differences already at this early time point. The finding that sex-dependent 
disparities in systolic function begin to manifest early after the onset of LVH is supported 
by a former study from Weinberg et al. (117). In their isolated heart experiment, they 
observed a better preserved LV contractile reserve capacity in female rats compared to 
male ones after 6 weeks of AB. 
In good agreement with previous studies, our investigation revealed that sex-related 
differences in LV systolic function became more pronounced at a later stage of PO-
induced LVH. Accordingly, at week 12 the contractility augmentation diminished in male 
AB rats, resulting in a mismatch between the LV and the connecting arterial system 
(impaired VAC ratio). The transition from compensated LVH to systolic HF was also 
reflected by the reduction of load-dependent systolic parameters (EF) in male AB rats. 
On the contrary, female AB rats demonstrated enhanced LV contractility (increased 
ESPVR and PRSW) after 12 weeks of PO. The contractility augmentation in female AB 
animals resulted in a maintained VAC and preserved global systolic function (EF) despite 
the chronically increased arterial afterload.  
 
6.3.3. Sex differences in left ventricular diastolic function under pressure 
overload 
Previous studies have raised the possibility that sex differences may also exist in LV 
diastolic function in case of PO-induced LVH (109). However, to date only a few studies 
have sought to assess different aspects of LV diastolic function in male and female 
patients or experimental animals with LVH.   
Active relaxation. Detailed analysis of P-V loops provided evidence that the 
development of LVH was associated with prolongation of active relaxation (as assessed 
by the Tau, the active relaxation time constant) in both sexes. Of particular interest, 
impairment of ventricular relaxation was already detected at week 6, becoming even more 
pronounced at week 12. The PO-related changes in Tau among male rats were identical 




(in Study 1 and 2).  However, the finding of impaired active relaxation in female rats with 
sustained PO was novel. Furthermore, we found that the severity of diastolic dysfunction 
was similar in the two sexes at week 6. In contrast, at week 12 we detected significantly 
greater prolongation of Tau in male AB rats when compared to their female littermates. 
Our functional results may be underpinned by previous molecular experiments, indicating 
sex-specific regulation of sarco/endoplasmic reticulum Ca2+-ATPase during the 
development of LVH (117). 
Passive filling. Both clinical and preclinical findings suggest that male sex is associated 
with a more severe deterioration of the passive diastolic properties of the LV under 
sustained PO. Accordingly, Villari et al. documented impaired myocardial stiffness in 
male but not in female patients with long-standing AS (109). Furthermore, experimental 
studies have observed that elevation of LVEDP accompanies the development of LVH in 
male animals, whereas in females LVEDP remains at physiologically low levels despite 
the manifestation of pathological hypertrophy. Considering that myocardial compliance 
(the passive expansion capability of the LV) is primarily determined by the structural 
composition of the ventricular wall, the characteristic sex-related discrepancies in passive 
filling have been predominantly attributed to the differences in ECM remodeling. In the 
current study, we also observed that the slope of EDVPR (marker of chamber stiffness) 
and LVEDP was only increased in the male AB-wk12 group. Importantly, it was also 
found that interstitial fibrosis occurred to a greater extent in the male AB group at week 
12. Hence, the impairment of the passive diastolic properties of the LV in male AB rats 
may have indeed originated from maladaptive myocardial ECM remodeling. This 
conclusion was also strengthened by the fact that a strong correlation was discovered 
between fibrosis and ventricular stiffness parameters among the study groups. 
6.4. Limitations 
One possible limitation of the studies might be that the gradual rise of arterial blood 
pressure (proximal to the aortic constriction) has not been registered. However, literature 
data clearly indicate that in the abdominal AB rat model, a substantial increment of 
arterial blood pressure occurs already in the first 2 weeks after the surgical application of 
the constriction (144). Therefore, it can be confidently stated that the severe increment in 
afterload had been long persisted before the selected time points (weeks 6, week 12 and 




Furthermore, it has to be also noted here that the AB rat model involves numerous 
mechanistic components that ultimately evoke the pathological remodeling of the LV. 
Accordingly, previous investigations have indicated that constricting the abdominal aorta 
at the suprarenal level not only induces PO in the proximal part of the aorta but also leads 
to the hypoperfusion of the kidneys with subsequent activation of the renin-angiotensin-
aldosterone system (145, 146). Therefore, it cannot be ruled out that in our study, neuro-
humoral factors also contributed to the development of LVH. 
In study 2 a relatively short follow-up period (6 weeks) was utilized to detect the 
functional consequences of myocardial reverse remodeling. Therefore, further research is 
warranted to test whether the observed differences between the early and the late 
debanded groups also exist after a substantially longer period of time.  
In study 3, a standard size was used to induce PO in rats. However, male animals grew 
to a greater body size, which raised the possibility that in male rats a relatively more 
severe aortic constriction developed. Therefore, to exclude the possibility of different 
degrees of PO in male and female rats, numerous parameters of afterload were calculated 
(SBP, DBP, MAP, and Ea), which showed no differences between the sexes. 
Accordingly, it could be hypothesized that indeed genetic and hormonal factors have 






Ample evidence supports the notion that termination of the pathological stimulus of 
PO could result in a state of reverse remodeling. Nevertheless, it has been also recognized 
that not all the patients experience the same extent of functional and structural 
improvement following pressure unloading therapy. Hence, efforts have been taken to 
identify factors which might influence the regression of LVH. These studies have 
indicated that the time point of medical interventions and the sex of the patients might 
determine the success of the reverse remodeling process. 
One of the main conclusions of our experiments is that pressure unloading therapy at 
both early and late time points effectively improves LV systolic function. By performing 
invasive P-V analysis we confirmed that increased arterial afterload and not depressed 
LV contractility underpins the reduced systolic performance even at advanced stages of 
PO-induced LVH in the abdominal AB rat model. Hence, terminating the PO at both early 
and late time points rapidly normalizes the relation between the contractile state of the 
LV and the afterload of the connecting arterial system.  
In contrast to systolic function, we found that diastolic function (both active relaxation 
and myocardial stiffness) recovers to a greater extent in case of early debanding compared 
to late debanding. This finding might be explained by the fact that the early pressure 
unloading therapy entailed a more complete structural reverse remodeling compared to 
the late-stage surgery. Accordingly, regression of reactive interstitial and perivascular 
fibrosis was only detected in the early debanded group, while it persisted in the late 
debanded group. These results call attention to the fact that performing pressure unloading 
therapy (AVR, TAVI) at an earlier time point may be superior in regard to normalization 
of diastolic function.  
Furthermore, the sex of the patients has been also suggested to influence the outcome 
of pressure unloading therapies. Here, we confirmed that the advanced stage of PO-
induced LVH is associated with less myocardial fibrosis as well as less severely impaired 
LV active relaxation and myocardial stiffness in female compared to male AB rats. As 
interstitial fibrosis and diastolic dysfunction have been found to be those factors, which 
display less reversibility after pressure unloading, our results might indicate that women 






PO-induced pathological LVH regresses after pressure unloading. Nevertheless, it has 
been recognized that in some patients, LV dysfunction and HF symptoms persist even 
after optimal medical therapy. Of particular interest, current guidelines recommend AVR 
only in case of severe AS, when HF symptoms are present and/or LV systolic function is 
reduced (EF<50%). In the frame of the present investigation we demonstrated that the 
severe stage of PO-induced LVH (that recapitulates the clinical situation of those patients 
who are eligible for AVR) was associated with robust myocardial hypertrophy, intensified 
collagen accumulation, reduced systolic function and marked diastolic dysfunction 
(prolonged active relaxation and impaired myocardial stiffness) in the abdominal AB rat 
model. Importantly, pressure unloading at this advanced stage of LVH efficiently reduced 
the extent of myocardial hypertrophy. Similarly, a complete recovery of LV systolic 
function was also observed. On the contrary myocardial fibrosis failed to regress during 
the 6-week long follow-up period. The incomplete regression of reactive fibrosis impeded 
the recovery of both the active and the passive components of diastolic function. To test, 
whether an earlier intervention could be more beneficial compared to late-stage surgery, 
we have investigated the reverse remodeling process after terminating the PO at an earlier 
time point (before severe ECM remodeling took place). Importantly we found that early 
pressure unloading resulted in a significantly greater improvement of both active 
relaxation and myocardial stiffness. Hence, our results call attention to the importance of 
early interventions in case of PO-induced LVH. 
Besides the timing of pressure unloading therapies, recent studies have shed light on 
the notion that the sex of the patient might be another important determinant of the reverse 
remodeling process. This is underpinned by the fact that due to a substantially slower 
disease progression, early stage characteristics of LVH (with relatively low level of 
myocardial fibrosis) are more often observed in female patients and experimental animals 
compared to their male counterparts. In the current investigation we yielded evidence that 
PO-induced LVH in female rats was associated with better LV contractility and systolic 
function as well as less severely impaired active relaxation and myocardial stiffness. 
Considering that diastolic dysfunction displays poor reversibility, the less deteriorated 
active relaxation and myocardial stiffness in female animals might indicate a greater 





A fokozott nyomásterhelés által indukált patológiás bal kamra (BK) hipertrófia (BKH) 
a nyomásterhelés megszüntetése után visszaalakul. Ugyanakkor kutatások igazolják, 
hogy egyes betegekben a szívelégtelenség tünetei és a BK-i diszfunkció a megfelelő 
terápiás beavatkozások után is fennállnak. Erre magyarázatul szolgálhat, hogy a jelenleg 
érvényes ajánlások aorta stenosis fennállása esetében csak igen súlyos, előrehaladott 
állapotban (amikor a szívelégtelenség tünetei már megjelentek és/vagy a szisztolés 
funkció jelentősen károsodott) javasolják a műtéti beavatkozást. Jelen 
patkánykísérletünkben a BKH súlyos, előrehaladott stádiumát nagymértékű 
szívizomhipertrófia, fokozott fibrózis, csökkent szisztolés funkció és súlyosan károsodott 
diasztolés funkció (megnyúlt aktív relaxáció és fokozott miokardiális stiffness) 
jellemezte. Ebben a stádiumban végrehajtott nyomásterhelés-csökkentő terápia a 
szívizomhipertrófia jelentős regresszióját eredményezte. Ezzel párhuzamosan a szisztolés 
funkció szintén teljes mértékben helyreállt. Ugyanakkor, a BKH késői stádiumából a 
fokozott kollagén felhalmozódás nem mutatott csökkenést. Hemodinamikai méréseink 
rávilágítottak arra, hogy a perzisztáló miokardiális fibrózis gátolta a diasztolés funkció 
mindkét aspektusának (aktív relaxáció és passzív telődés) a javulását. 
Patkánymodellünkben ezért megvizsgáltuk, hogy vajon egy korábban kezdett 
nyomásterhelés-csökkentő terápia nagyobb mértékű funkcionális regenerációt biztosíthat 
a jelenleg alkalmazott késői beavatkozással szemben. Érdekes módon azt találtuk, hogy 
a korai terápia a diasztolés funkció szignifikánsan nagyobb mértékű javulását 
eredményezte a késői műtéttel szemben. Eredményeink ezért felhívják a figyelmet a korai 
beavatkozások szükségességére fokozott nyomásterhelés indukálta BKH esetén.   
Az elmúlt években világossá vált, a női nem szintén fontos befolyásoló hatással bírhat 
a BKH visszaalakulására. Ennek hátterében az áll, hogy nők esetében a fokozott 
nyomásterhelés hatására eltérő változások játszódnak le a szívizomban. Ezt igazolja, hogy 
női betegekben kisebb mértékű fibrózist és kedvezőbb BK-i geometriát írtak le férfi 
beteghez képest. Jelen kísérletünkben megfigyeltük, hogy nőstény patkányokban a BKH 
késői stádiumára jobb BK-i kontraktilitás és szisztolés teljesítőképesség valamint kevésbé 
károsodott aktív relaxáció és falmerevség volt jellemző. A diasztolés funkció kisebb 
mértékű károsodása felveti a lehetőségét, hogy nőkben a nyomásterhelés-csökkentő 
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